

Petition for *Inter Partes* Review of  
U.S. Patent No. 9,732,149 B2

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

SAMSUNG BIOEPIS CO., LTD.,  
Petitioner

v.

ALEXION PHARMACEUTICALS, INC.,  
Patent Owner

---

Case IPR2023-00933  
U.S. Patent No. 9,732,149 B2  
Issue Date: August 15, 2017

Title: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY  
AN INHIBITOR OF COMPLEMENT

**PETITION FOR *INTER PARTES* REVIEW  
OF U.S. PATENT NO. 9,732,149 B2**

## Table of Contents

	Page
I. INTRODUCTION .....	1
II. MANDATORY NOTICES UNDER §42.8(A)(1) .....	2
A. Real Party-In-Interest under §42.8(b)(1).....	2
B. Related Matters under §42.8(b)(2) .....	2
C. Lead and Back-Up Counsel under §42.8(b)(3) .....	2
D. Service Information .....	3
III. FEE PAYMENT .....	3
IV. REQUIREMENTS UNDER §§42.104 AND 42.108.....	3
A. Standing.....	3
B. Identification of Challenge.....	3
V. FACTUAL BACKGROUND.....	4
A. Antibody Structure and Humanization of Antibodies.....	4
B. By 2007, the C5-Binding Antibody Called Eculizumab Was Known as a Treatment for PNH.....	5
C. As of the 2007 Priority Date, Alexion Believed the Sequence of Eculizumab Had Been Publicly Disclosed.....	6
D. Eculizumab Development and Naming History .....	7
VI. OVERVIEW OF THE '149 PATENT .....	12
A. Person of Ordinary Skill in the Art .....	12
B. Overview of the Specification.....	13
C. '149 Prosecution History.....	13
VII. CLAIM CONSTRUCTION .....	15
VIII. THE CHALLENGED CLAIM IS UNPATENTABLE .....	15
A. Prior Art References Cited in Proposed Grounds .....	15

**Table of Contents**  
(continued)

	<b>Page</b>
1. Bowdish [EX1004] .....	15
2. Evans [EX1005] .....	16
3. Bell [EX1007] .....	18
4. Tacken [EX1008] .....	18
5. Mueller PCT [EX1009] .....	18
B. Overview of Proposed Grounds for IPR .....	20
C. Ground 1: Claim 1 Is Anticipated by Bowdish .....	22
D. Ground 2: Claim 1 Is Obvious Over Bowdish and Evans in view of Bell, Tacken, and Mueller PCT .....	26
E. Ground 3: Claim 1 Is Obvious Over Evans and Mueller PCT in view of Bell and Tacken .....	35
F. Ground 4: Claim 1 Is Anticipated by Bell .....	40
1. Bell Necessarily Discloses SEQ ID NOS:2 and 4, the Anti-C5 Antibody Known as Eculizumab .....	41
2. The Prior Art Enabled the Eculizumab Sequences Inherently Disclosed in Bell .....	44
IX. NO SECONDARY CONSIDERATIONS OF NONOBVIOUSNESS .....	45
X. THE BOARD SHOULD REACH THE MERITS OF THE PETITION .....	48
A. §314(a) .....	49
B. §325(d) .....	49
1. Evaluation of Art and Arguments During '149 Prosecution .....	50
2. Evaluation of Art and Arguments During Prosecution of '189 Child Patent .....	53
(a) Error 1: The Examiner Overlooked Tacken and Mueller PCT .....	54

**Table of Contents**  
(continued)

	<b>Page</b>
(b) Error 2: The Examiner Erred in Evaluating Bowdish and Evans .....	56
(c) Error 3: The Examiner Misapplied the Law in Evaluation of Secondary Considerations.....	60
XI. CONCLUSION.....	61

**List of Exhibits**

<b>Exhibit No.</b>	<b>Description of Document</b>
<b>1001</b>	U.S. Patent No. 9,732,149 B2 issued to Leonard Bell et al. (filed Oct. 3, 2016, issued Aug. 15, 2017) (“149 patent”)
<b>1002</b>	Prosecution History for U.S. Patent No. 9,732,149 B2
<b>1003</b>	Declaration of Jeffrey V. Ravetch, M.D., Ph.D.
<b>1004</b>	U.S. Patent Application Publication No. 2003/0232972 A1 issued to Katherine S. Bowdish et al. (filed Dec. 2, 2002, published Dec. 18, 2003) (“Bowdish”)
<b>1005</b>	U.S. Patent No. 6,355,245 B1 issued to Mark J. Evans et al. (filed June 7, 1995, issued Mar. 12, 2002) (“Evans”)
<b>1006</b>	John P. Mueller et al., <i>Humanized Porcine VCAM-Specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells</i> , 34 Molecular Immunology 441 (1997) (“Mueller 1997”)
<b>1007</b>	U.S. Patent Application Publication No. 2005/0191298 A1 issued to Leonard Bell et al. (filed Feb. 3, 2005, published Sept. 1, 2005) (“Bell”)
<b>1008</b>	Paul J. Tacken et al., <i>Effective induction of naive and recall T-Cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody</i> , 106 Blood 1278 (2005) (“Tacken”)
<b>1009</b>	World Intellectual Property Organization International Publication No. WO 97/11971 issued to John P. Mueller et al. (filed Sept. 27, 1996, published Apr. 3, 1997) (“Mueller PCT”)
<b>1010</b>	Thomas C. Thomas et al., <i>Inhibition of Complement Activity By Humanized Anti-C5 Antibody and Single-Chain Fv</i> , 33 Molecular Immunology 1389 (1996) (“Thomas”)

**List of Exhibits**

<b>Exhibit No.</b>	<b>Description of Document</b>
<b>1011</b>	Peter Hillmen et al., <i>Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria</i> , 350 N. Engl. J. Med. 552 (2004) (“Hillmen 2004”)
<b>1012</b>	Anita Hill et al., <i>Abstract# 2823: Sustained Control of Hemolysis and Symptoms and Reduced Transfusion Requirements over a Period of 2 Years in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab Therapy</i> , 104 Blood 772a (2004) (“Hill 2004”)
<b>1013</b>	Anita Hill et al., <i>Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria</i> , 106 Blood 2559 (“Hill 2005”)
<b>1014</b>	Peter Hillmen et al., <i>The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria</i> , 355 N. Engl. J. Med. 1233 (2006) (“Hillmen 2006”)
<b>1015</b>	Neal S. Young et al., <i>Abstract# 971: Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study</i> , 108 Blood 290a (2006) (“Young”)
<b>1016</b>	Peter Hillmen et al., <i>Abstract# 154: Eculizumab, a C5 Complement-Blocking Antibody, Abolishes Hemolysis and Renders Hemolytic Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Transfusion Independent</i> , 100 Blood 44a (2002) (“Hillmen 2002”)
<b>1017</b>	Peter Hillmen et al., <i>Abstract# 1858: Eculizumab, a C5 Complement-Blocking Antibody, Controls Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Responses Maintained Over a Prolonged Period of Therapy</i> , 102 Blood 509a (2003) (“Hillmen 2003”)
<b>1018</b>	Excerpts from <i>Recommended INN List 49, International Nonproprietary Names for Pharmaceutical Substances</i> , 17 WHO Drug Information 115, World Health Organization (2003)

**List of Exhibits**

<b>Exhibit No.</b>	<b>Description of Document</b>
<b>1019</b>	<i>Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances</i> , Programme on International Nonproprietary Names (INN), Division of Drug Management & Policies, World Health Organization, Geneva (1997)
<b>1020</b>	Alexion Press Release, <i>Alexion Issued Key C5 Complement Inhibitor Patent for Inflammatory Diseases</i> (Mar. 15, 2002), <a href="https://web.archive.org/web/20030621141230/http://www.alxn.com/products/index.cfm">https://web.archive.org/web/20030621141230/http://www.alxn.com/products/index.cfm</a>
<b>1021</b>	World Intellectual Property Organization International Patent Publication No. WO 2005/007809 A2 issued to Russell P. Rother et al. (filed May 28, 2004, published Jan. 27, 2005)
<b>1022</b>	World Intellectual Property Organization International Patent Publication No. WO 2005/110481 A2 issued to Russell P. Rother et al. (filed May 16, 2005, published Nov. 24, 2005)
<b>1023</b>	Mariana Kaplan, <i>Eculizumab Alexion</i> , 3 Curr. Opin. Investig. Drugs 1017 (2002)
<b>1024</b>	<i>Amgen, Inc. v. Alexion Pharmaceuticals</i> , IPR2019-00741, Paper 15, Decision – Institution of <i>Inter Partes</i> Review (PTAB Aug. 30, 2019)
<b>1025</b>	<i>Amgen, Inc. v. Alexion Pharmaceuticals, Inc.</i> , IPR2019-00741, Paper 22, Patent Owner Response Pursuant to 37 C.F.R. § 42.120 (PTAB Nov. 22, 2019)
<b>1026</b>	<i>Amgen, Inc. v. Alexion Pharmaceuticals</i> , IPR2019-00741, Paper 48, Termination – Due to Settlement After Institution of Trial (PTAB June 1, 2020)
<b>1027</b>	Opposition File History for European Patent No. 1 720 571 B1
<b>1028</b>	File History for European Patent No. 3 167 888

**List of Exhibits**

<b>Exhibit No.</b>	<b>Description of Document</b>
<b>1029</b>	Excerpt from the File History for U.S. Patent Application No. 11/127,438, Amendment in Response to Non-Final Office Action (Aug. 2, 2011)
<b>1030</b>	Application for Extension of Patent Term under 35 U.S.C. § 156 and 37 CFR § 1.740, U.S. Patent No. 6,355,245, Alexion Pharmaceuticals (May 11, 2007)
<b>1031</b>	Certificate Extending Patent Term, U.S. Patent No. 6,355,245 (June 11, 2010)
<b>1032</b>	Excerpt from the File History of U.S. Patent No. 10,590,189, Information Disclosure Statement by Applicant, considered by Examiner James L Rogers, May 31, 2019
<b>1033</b>	Esther M. Yoo et al., <i>Human IgG2 Can Form Covalent Dimers</i> , 170 J. Immunol. 3134 (2003) (“Yoo 2003”)
<b>1034</b>	Excerpt from the File History of U.S. Patent No. 10,590,189, Non-Final Rejection, mailed June 11, 2019
<b>1035</b>	Excerpt from the File History of U.S. Patent No. 10,590,189, Notice of Allowance, mailed Jan. 22, 2020
<b>1036</b>	Excerpt from the File History of U.S. Patent No. 10,590,189, Amendment in Response to Non-Final Office Action Under 37 C.F.R. § 1.111, mailed Dec. 11, 2019
<b>1037</b>	Jette Wypych et al., <i>Human IgG2 Antibodies Display Disulfide-mediated Structural Isoforms</i> , 283 J. Biol. Chem. 16194 (2008) (“Wypych”)
<b>1038</b>	Stylianos Bournazos et al., <i>Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection</i> , 588 Nature 485 (2020) (“Bournazos 2020”)



**List of Exhibits**

<b>Exhibit No.</b>	<b>Description of Document</b>
<b>1039</b>	Stylianios Bournazos et al., <i>Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity</i> , 124 J. Clinical Investigation 725 (2014) (“Bournazos 2014”)
<b>1040</b>	Lucie Baudino et al., <i>Impact of a Three Amino Acid Deletion in the CH2 Domain of Murine IgG1 on Fc-Associated Effector Functions</i> , 181 J. Immunology 4107 (2008)
<b>1041</b>	Toshiyuki Takai et al., <i>FcR <math>\gamma</math> Chain Deletion Results in Pleiotropic Effector Cell Defects</i> , 76 Cell 519 (1994)
<b>1042</b>	Falk Nimmerjahn & Jeffrey V. Ravetch, <i>Fc<math>\gamma</math> receptors as regulators of immune responses</i> , 8 Nat. Rev. Immunol. 34 (2008)
<b>1043</b>	Jeffrey V. Ravetch & Jean-Pierre Kinet, <i>Fc Receptors</i> , 9 Annu. Rev. Immunol. 457 (1991)
<b>1044</b>	<i>Reserved</i>
<b>1045</b>	Charles A. Janeway, Jr. et al., <i>Chapter 1: Basis Concepts in Immunology</i> , and <i>Chapter 3: Antigen Recognition by B-cell and T-cell Receptors</i> , Immunobiology: the immune system in health and disease, pp. 1-34, 93-122 (5th ed. 2001)
<b>1046</b>	Excerpts from Pei-Show Juo, Ph.D., Concise Dictionary of Biomedicine and Molecular Biology (2nd ed. 2001)
<b>1047</b>	Tina Völkel et al., <i>Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies</i> , 14 Protein Engineering 815 (2001) (“Völkel”)
<b>1048</b>	Evelyn D. Lobo et al., <i>Antibody Pharmacokinetics and Pharmacodynamics</i> , 93 Journal of Pharmaceutical Sciences 2645 (2004) (“Lobo 2004”)

**List of Exhibits**

<b>Exhibit No.</b>	<b>Description of Document</b>
<b>1049</b>	Neil S. Lipman et al., <i>Monoclonal Versus Polyclonal Antibodies: Distinguishing Characteristics, Applications, and Information Resources</i> , 46 ILAR Journal 258 (2005) (“Lipman 2005”)
<b>1050</b>	Benny K.C. Lo, <i>Chapter 7: Antibody Humanization by CDR Grafting</i> , Methods in Molecular Biology, Vol. 248: Antibody Engineering: Methods and Protocols, pp. 135-159 (2004) (“Lo 2004”)
<b>1051</b>	Lutz Riechmann et al., <i>Reshaping human antibodies for therapy</i> , 332 Nature 323 (1988) (“Riechmann”)
<b>1052</b>	Janice M. Reichert, <i>Marketed therapeutic antibodies compendium</i> , 4 mAbs 413 (2012) (“Reichert”)
<b>1053</b>	Bruce Alberts et al., <i>Chapter 12: Intracellular Compartments and Protein Sorting</i> , Molecular Biology of the Cell, pp. 551-98 (1994)
<b>1054</b>	Elisabeth E. Adderson et al., <i>Immunoglobulin Light Chain Variable Region Gene Sequences for Human Antibodies to Haemophilus influenzae Type b Capsular Polysaccharide Are Dominated by a Limited Number of <math>V_{\kappa}</math> and <math>V_{\lambda}</math> Segments and VJ Combinations</i> , 89 J Clin. Invest. 729 (1992)

Petition for *Inter Partes* Review of  
U.S. Patent No. 9,732,149 B2

Petitioner respectfully requests institution of *inter partes* review (IPR) of U.S. Patent No. 9,732,149 B2 (“’149 patent” or “EX1001”), claim 1, as shown below.

**I. INTRODUCTION**

The ’149 patent never should have issued. Its sole claim covers, as a composition of matter, the heavy and light chains of the antibody known as eculizumab. Years before 2007, eculizumab was known as an anti-C5 antibody that was an effective treatment for the debilitating condition called paroxysmal nocturnal hemoglobinuria (“PNH”). And despite Alexion’s recent efforts to argue that the scientific community did not know the amino acid sequence of eculizumab before the March 15, 2007 priority date, the sequence was in fact available to researchers long before that date. Several prior art publications disclose outright the exact sequence of eculizumab by providing a simple roadmap for its assembly, rendering the claim anticipated and obvious. The claim was also inherently anticipated by published Alexion patent applications and clinical trials using eculizumab.

Arguments similar (but not identical) to those presented here were the basis of a previous IPR pursued by Amgen, Inc., which was instituted. That IPR never reached a final written decision because the parties settled and the IPR was terminated. As explained below, IPR should again be instituted against the ’149 patent to prevent Alexion from asserting the patent to an antibody sequence that was firmly in the public domain long before Alexion filed its patent application.

## **II. MANDATORY NOTICES UNDER §42.8(A)(1)**

### **A. Real Party-In-Interest under §42.8(b)(1)**

Samsung Bioepis Co., Ltd. is the real party-in-interest to this IPR petition.

### **B. Related Matters under §42.8(b)(2)**

The '149 patent is not currently involved in any litigation or Patent Office proceedings. An *inter partes* review of the '149 patent filed by Amgen, Inc. was instituted as IPR2019-00741 ("Amgen IPR"). (EX1024.) No final written decision was issued because the Amgen IPR was terminated following settlement. (EX1026.)

### **C. Lead and Back-Up Counsel under §42.8(b)(3)**

Petitioner provides the following designation of counsel.

<b>LEAD COUNSEL</b>	<b>BACK-UP COUNSEL</b>
Michelle S. Rhyu (Reg. No. 41,268) rhyums@cooley.com COOLEY LLP ATTN: Patent Group 1299 Pennsylvania Ave. NW, Suite 700 Washington, DC 20004 Tel: (650) 843-5505 Fax: (650) 849-7400	Daniel J. Knauss (Reg. No. 56,393) dknauss@cooley.com COOLEY LLP ATTN: Patent Group 1299 Pennsylvania Ave. NW, Suite 700 Washington D.C. 20004 Tel: (650) 843-5287 Fax: (650) 849-7400
	Priya Arora (Admission <i>pro hac vice</i> to be requested) parora@cooley.com COOLEY LLP ATTN: Patent Group 1299 Pennsylvania Avenue NW Suite 700 Washington D.C. 20004 Tel: (650) 843-5384 Fax: (650) 849-7400

**D. Service Information**

This Petition is being served by Federal Express to the attorney of record for the '149 patent, NELSON MULLINS RILEY & SCARBOROUGH LLP, One Financial Center, Ste. 3500, Boston, MA 02111. Petitioner consents to electronic service at the addresses provided above for counsel.

**III. FEE PAYMENT**

Petitioner requests review of 1 claim, with a \$41,500 payment.

**IV. REQUIREMENTS UNDER §§42.104 AND 42.108**

**A. Standing**

Petitioner certifies that the '149 patent is available for IPR and that Petitioner is not barred or otherwise estopped.

**B. Identification of Challenge**

Petitioner requests institution of IPR of claim 1 based on the following grounds:


Ground	Claim	Basis for Challenge
1	1	Anticipated by Bowdish (EX1004)
2	1	Obvious over Bowdish and Evans (EX1005) in view of Bell (EX1007), Tacken (EX1008), and Mueller PCT (EX1009)
3	1	Obvious over Evans and Mueller PCT in view of Bell and Tacken
4	1	Anticipated by Bell

Submitted with this petition is the declaration of Jeffrey V. Ravetch, M.D.  
Ph.D., a qualified expert. (EX1003, ¶¶1-14, Ex. A.)

## V. FACTUAL BACKGROUND

### A. Antibody Structure and Humanization of Antibodies


As relevant here, an antibody consists of two pairs of amino acid chains referred to as heavy and light chains. (EX1003, ¶¶35-36.) Each of these chains has a constant and a variable domain. (EX1003, ¶37; EX1046, 004-05, 006.) The variable domains contain subportions responsible for antigen recognition called Complementarity-Determining Regions (“CDRs”); there are three CDRs each in the variable domains of each heavy and light chain, as shown below:



(EX1003, ¶38; EX1045, 055–57.)

The variable regions of the heavy and light chains are abbreviated as “V<sub>H</sub>”

and “V<sub>L</sub>.” The constant region of the heavy chain is broken up into subregions called CH1, CH2, and CH3. CH1 is separated from CH2 and CH3 by a hinge region, as shown below.



Basic domain structure of antibody

(EX1003, ¶¶40-44.) Well before 2007, the process of “humanization” of antibodies – in which mouse antibodies to human targets were converted into mostly human sequences while retaining target-binding function – was well known and routinely practiced by artisans developing antibodies for use as therapies in humans. (EX1003, ¶¶49-54; *see also* EX1049, 010-12; EX1051; EX1052.)

**B. By 2007, the C5-Binding Antibody Called Eculizumab Was Known as a Treatment for PNH**

PNH is a disease of blood cells caused by a genetic mutation that renders the cells more susceptible to destruction by the complement system. (EX1007, [0005];

EX1013, 009.) It is characterized by paroxysmal nocturnal (sudden attacks in the night) hemoglobinuria (hemoglobin in the urine, causing dark coloring). (*Id.*; EX1007, [0007].) Other known clinical symptoms include anemia, fatigue, thrombosis, and pain. (EX1007, [0007]; EX1013, 009; EX1011, 004.) Inhibition of the complement cascade at the step in which C5 is converted to C5a and C5b was recognized as useful for inhibiting PNH symptoms, while retaining upstream complement system activity necessary for immune system function and clearance of microorganisms. (EX1013, 009; EX1011, 004; EX1003, ¶¶55-56.)

By March 15, 2007, one known inhibitor of C5 conversion was the anti-C5 antibody eculizumab. Indeed, more than a year before the '149 patent was filed, at least three clinical publications disclosed that eculizumab was a useful treatment for PNH. (EX1007, [0052]; EX1013, 009; EX1011, 003; EX1003, ¶57; *see also* EX1014; EX1015; EX1012; EX1017; EX1016.)

**C. As of the 2007 Priority Date, Alexion Believed the Sequence of Eculizumab Had Been Publicly Disclosed**

By seeking a patent on the amino acid sequence of eculizumab, Alexion represented to the patent office that the sequence was novel and nonobvious, but this was not so. On the contrary, Alexion presumably intended to disclose the full amino acid sequence of eculizumab in 1999 and made a submission to Chemical Abstracts Services (“CAS”) for that purpose. In Alexion’s words to the European Patent Office, “the sequence for eculizumab was publicly available [before Feb. 3, 2004],”



and the “sequence for eculizumab was submitted to [CAS] and entered into their STN database on 14 February 1999.” (EX1027, 277, 291 (5.1.2.); EX1003, ¶58.) Alexion later claimed in an European counterpart patent application in this family that it was not until ten years later, in 2009, that Alexion “learned” that the sequence for eculizumab had “inadvertently” been submitted with errors in the sequences. (EX1028, 235-42, 280-81.)<sup>1</sup>

Even setting aside the implausibility of Alexion’s ten-year delay in discovering that it had submitted erroneous sequence information to CAS, as discussed in Part VIII below, the prior art still anticipated and rendered these sequences obvious. (EX1003, ¶59.)

#### **D. Eculizumab Development and Naming History**

When first identified as a mouse antibody that specifically binds C5, Alexion scientists gave it the name “5G1.1.” (EX1010, 006-07.) This mouse antibody was then “humanized,” meaning that the CDR domains responsible for C5 binding were grafted into a human “framework” variable region, using techniques that were well-developed by the mid-1990s. (EX1010, 007-08; EX1003, ¶¶54, 60; *see also*

---

<sup>1</sup> The EPO refused to grant the application, in part based on its conclusion that “[e]culizumab is considered to have been available to the public before the filing date of the present application.” (EX1028, 1444.)

EX1050, 010-12; EX1051; EX1052.) The resulting humanized antibody maintains fully mouse sequences in each of its six CDR domains, but otherwise uses human sequences for the variable region to varying degrees; this antibody was given the name “h5G1.1” by Alexion. (EX1010, 010-12; *see also* EX1005, 43:6-14, 43:62-45:4.) After confirming that the humanized antibody variable domain retained its C5-binding function, Alexion scientists assembled it into a full-length antibody of the human IgG4 isotype, which they named “h5G1.1 HuG4.” (EX1010, 013; EX1003, ¶60.)

Soon after creating this antibody, Alexion set about improving it by modifying the constant region to give it a hybrid IgG2/IgG4 backbone. (EX1006, 013-14; *see also* EX1009, 014, 097 (referencing “h5G1.1 G2/G4”).) Alexion sought to reduce or eliminate binding by the constant region of the IgG4 isotype to other proteins such as FcR and C1q that are involved in human immune responses and the complement system, by replacing it with comparable IgG2 sequences. (EX1006, 015-16; EX1003, ¶¶45-48, 61; *see also* EX1048, 013-14.) Specifically, the improved antibody contained the CH1 and hinge region from IgG2 and the CH2 and CH3 regions from IgG4; Alexion again confirmed that this modification did not impact binding to C5. (EX1006, 015-16.) Alexion called this antibody “h5G1.1 HuG2/G4.” (*Id.*; EX1003, ¶61.) In a companion patent application describing the same work, Alexion referred to this antibody interchangeably as “h5G1.1 G2/G4”

Petition for *Inter Partes* Review of  
U.S. Patent No. 9,732,149 B2

and “h5G1.1 CO12 HuG2/G4.” (EX1009, 014, 097; EX1003, ¶61.)


By 2002, Alexion had obtained a unique name for this antibody pursuant to the World Health Organization’s guidelines for international nonproprietary names (“INNs”). Under INN rules in place since the 1990s, antibodies are named as follows: A random prefix of a few letters chosen by the product sponsor for uniqueness (in this case “ecu-”) is followed by a “sub-stem” indicating its function (immunomodulators use “-li-”), followed by another sub-stem indicating humanization (“-zu-”), finally followed by the stem “-mab” applied to all monoclonal antibodies. (EX1019, 031-32.) Thus, Alexion’s antibody received the nonproprietary name ecu-li-zu-mab. (EX1003, ¶62.)

Publications and statements by Alexion and others before 2007 clearly disclosed that the humanized 5G1.1 antibody *with* a hybrid G2/G4 constant domain was eculizumab. The Tacke reference referring to eculizumab as Alexion’s “potential product” specifically identified eculizumab as the h5G1.1 antibody with an “IgG2/IgG4 constant region.” (EX1008, 010-11.) Tacke further cited to the Mueller 1997 article discussed above, which discloses the conversion of h5G1.1 to

the HuG2/G4 form. (EX1008, 011, 017 (ref. 17 (citing EX1006)); EX1003, ¶63.)<sup>2</sup> Similarly, in a 2002 press release, Alexion announced the issuance of the Evans patent, which Alexion said “cover[s] the composition and use of Alexion’s lead drug candidate[] eculizumab (formerly known as 5G1.1).” (EX1003, ¶64; EX1020, 001; *see also* EX1022, 18:7-13.) Alexion also disclosed in Bowdish that it used the 5G1.1 antibody as a framework to create antibodies for other targets. (EX1004, [0191]; (EX1003, ¶66).) Bell uses parentheses to equate the two terms: “h5G1.1-mAb (eculizumab).” (EX1007, [0012]; EX1003, ¶67.) Likewise, a 2002 review of eculizumab identified its “synonyms” as 5G1.1 and h5G1.1. (EX1023, 001; EX1003, ¶65; *see also* EX1018, 011.) No reference states that “eculizumab” has exclusively IgG4 constant domain. A figure of the publications that discussed development of the 5G1.1 antibody before 2007 is shown below:

---

<sup>2</sup> Although Tacke includes an obvious typo in its spelling of eculizumab (“eculizamab”), under the INN guidelines discussed above there are no allowed names for antibodies with the stem “-zamab,” and any POSA would know that a humanized antibody such as eculizumab would have the stem “-zumab.” (EX1003, ¶63.)



(EX1003, ¶68.)

Alexion admitted in other patent office proceedings that “it was well-known to one of ordinary skill in the art [as of 2002] that eculizumab has a G2/G4 Fc portion, *i.e.*, a mutated Fc portion” and that “h5G1.1 ... [was] well-known to one of ordinary skill in the art as eculizumab.” (EX1029, 010-11; *see also* EX1003, ¶69.) Alexion based these statements on the disclosures of the same Evans and Mueller 1997 references discussed in the Grounds below. (*Id.*)

Alexion also stated publicly that its eculizumab/Soliris product corresponds to the sequences disclosed in the Evans patent. For example, Alexion announced in a 2002 press release that the Evans patent “cover[s] the composition and use of ... eculizumab (formerly known as 5G1.1).” (*See* EX1020, 001; EX1003, ¶64.) Having

to choose one patent for patent term extension for the eculizumab product (*see* 35 U.S.C. §156(c)(4)), Alexion chose Evans, not the '149 patent at issue here. In its application for PTE, Alexion represented that “U.S. Patent 6,355,245 [Evans] claims the Approved Product [eculizumab]” and provided a claim chart comparing the Evans patent claims to eculizumab (*See* EX1030, 004-07; EX1031 (granting term extension).)

## **VI. OVERVIEW OF THE '149 PATENT**

The '149 patent has one issued composition claim:

1. An antibody that binds C5 comprising a heavy chain consisting of SEQ ID NO: 2 and a light chain consisting of SEQ ID NO: 4.

(EX1001, 39:2-4; EX1003, ¶70.)

### **A. Person of Ordinary Skill in the Art**

A person of ordinary skill in the art (“POSA”) would have knowledge of the scientific literature and have skills relating to the design and generation of antibodies, the complement system, and the application of antibodies as therapeutics before March 15, 2007. (EX1003, ¶¶16-20.) A POSA also would have knowledge of laboratory techniques and strategies used in immunology research, including practical applications of the same. (*Id.*, ¶19.) Typically, a POSA would have had an M.D. and/or a Ph.D. in immunology, biochemistry, cell biology, molecular biology, pharmaceuticals, or a related discipline, with at least two years of experience in the discovery, development, and design of therapeutic antibodies for use as

potential treatments in human disease. (*Id.*) Also, a POSA may have worked as part of a multidisciplinary team and drawn upon not only his or her own skills, but also taken advantage of certain specialized skills of others on the team, *e.g.*, to solve a given problem; for example, a clinician, a doctor of pharmacy, and a formulation chemist may have been part of a team. (*Id.*)

### **B. Overview of the Specification**

The '149 patent describes the use of antibodies binding to the complement cascade protein C5 as a treatment for PNH. In particular, the '149 teaches that such antibodies “are known,” and that a preferred antibody is disclosed in the Evans reference and “now named eculizumab.” (EX1001, 12:26-29.) The patent describes details of the Phase 3 “TRIUMPH” clinical trial in which one such antibody, eculizumab, was evaluated in PNH patients. (EX1001, 19:53-28:35; EX1003, ¶71.) The patent also provides amino acid sequences for eculizumab’s heavy and light chains as SEQ ID NOS:2 and 4, respectively. (EX1001, Cols. 31-35; EX1003, ¶72.)<sup>3</sup>

### **C. '149 Prosecution History**

Alexion’s claim was initially rejected by the Examiner as inherently

---

<sup>3</sup> In addition to these sequences, the '149 also repeats these sequences in Column 30, but with an error in SEQ ID NO:2, the eculizumab heavy chain, that was corrected by a certificate of correction. (EX1002, 1354.)

anticipated by the clinical trial disclosed in Hillmen 2004 in view of the general knowledge in the art of eculizumab's sequence, as reflected in references such as Thomas. (EX1002, 1079-80.) The claim was also rejected as anticipated by (1) Appel et al., *Kidney International* 70, S45-S50, (2006) and (2) Wang et al., US2005/0271660. (EX1002, 1081; EX1003, ¶73.)

In response, Alexion wrongly asserted that “[n]either eculizumab nor its complete sequence, including the sequence of its unique, non-naturally occurring, protein-engineered heavy chain, was in the public domain prior to the March 15, 2007 effective filing date of the present application[.]” (EX1002, 1251.) Alexion also submitted evidence that the clinical trial reported in Hillmen 2004 was conducted confidentially such that its participants could not reveal the sequence of eculizumab. (EX1002, 1251-53; EX1003, ¶74.)

The Examiner allowed the claims based on the erroneous belief that prior art such as Hillmen 2004 did not “recite using an antibody which comprises a heavy chain consisting of SEQ ID NO: 2 and a light chain consisting of SEQ ID NO: 4 as currently recited and one of skill in the art would not have been easily guided to making antibodies with these recited sequences.” (EX1002, 1314; EX1003, ¶75.) As explained in this Petition and further in Part X.B below, this belief by the Examiner was erroneous and led to the issuance of an unpatentable claim. (*See infra* X.B; EX1003, ¶¶149-151.)



On February 28, 2019, Amgen challenged claim 1 of the '149 patent in IPR2019-00741. The Board instituted *inter-partes* review of claim 1. The parties' submissions and Board's findings during the *inter-partes* review were submitted to the PTO during prosecution of the '149 patent's child application that issued as U.S. Patent No. 10,590,189 ("'189 patent"). (EX1003, ¶76.)

## **VII. CLAIM CONSTRUCTION**

Petitioner does not believe claim construction is necessary at this time. The challenged claim recites an antibody that binds C5 "consisting of" specifically-defined heavy and light chain protein sequences. (EX1003, ¶70.)

## **VIII. THE CHALLENGED CLAIM IS UNPATENTABLE**

### **A. Prior Art References Cited in Proposed Grounds**

The priority date of the '149 patent is March 15, 2007.<sup>4</sup> Each reference in Grounds 1-4 (*see supra* IV.B) qualifies as prior art under 35 U.S.C. §102(b). (EX1003, ¶¶77-78.)


#### **1. Bowdish [EX1004]**

Bowdish is a US patent application, published on December 18, 2003, and is thus prior art under 35 U.S.C. §102(b). Bowdish's 5G1.1 antibody discloses outright

---

<sup>4</sup> Petitioner assumes this date for this Petition without waiving its right to challenge this priority date.

the light chain sequence (SEQ ID NO:4) in claim 1 of the '149 patent in Figure 13B. (EX1004, Fig. 13B; EX1003, ¶82.) Bowdish's 5G1.1 was also a starting point for making a new heavy chain that includes a "TPO mimetic peptide," as illustrated below. (EX1004, Fig. 13A & [0191]; EX1003, ¶79.)



That starting heavy chain sequence is described as having the sequence of Figure 13A with a substituted heavy chain CDR3 ("HCDR3") domain reported by Evans, which is incorporated by reference. That original sequence is identical to SEQ ID NO:2 of claim 1. (EX1003, ¶¶79-81, 83-84.)


## 2. Evans [EX1005]

Evans is a US patent issued on March 12, 2002, based on Application number 08/487,283. It is prior art under 35 U.S.C. §102(b). Evans is titled "C5-Specific Antibodies for the Treatment of Inflammatory Diseases." (EX1003, ¶85.) Example 11 provides eighteen constructs of "recombinant mAb-encoding DNAs." Of these,

Petition for *Inter Partes* Review of  
U.S. Patent No. 9,732,149 B2

nine constructs provide sequences for humanized 5G1.1 single-chain variable fragments (scFv), which correspond to V<sub>H</sub> and V<sub>L</sub> domains joined by a short peptide linker and starting with the “MA” leader sequence. (EX1005, 43:6-14, 43:61-45:4 (Example 11 (2) and (11)-(18)); EX1003, ¶¶39, 86; EX1047, 006.) The nine constructs disclose CDR sequences within the variable regions of humanized 5G1.1, and Evans’ CO12 scFv construct discloses the light and heavy chain variable domains of SEQ ID NOS:2 and 4 of claim 1:

Evans h5G1.1	1	DIQMTQSPSSLSASVGDRVTITCG	ASENIYGALN	WYQQKPGKAPKLLIYG	ATNLADGVPSRFS	SGSGSGTDFTLT	ISSLP	80	
'149 SEQ ID NO: 4	1	DIQMTQSPSSLSASVGDRVTITCG	ASENIYGALN	WYQQKPGKAPKLLIYG	ATNLADGVPSRFS	SGSGSGTDFTLT	ISSLP	80	
			CDR1		CDR2				
Evans h5G1.1	81	EDFATYYC	NVLNTP	TFGQGTKVEIKRT				109	
'149 SEQ ID NO: 4	81	EDFATYYC	NVLNTP	TFGQGTKVEIKRT	GGGGSGGGSGGGG			124	
			CDR3						
Evans h5G1.1	1	QVQLVQSGAEVKKPGASVKVS	CKASGYIFS	NYWIO	WVRQAPGQGLEWM	GEILPGSGSTEY	TENFKDRVT	MT	80
'149 SEQ ID NO: 2	125	QVQLVQSGAEVKKPGASVKVS	CKASGYIFS	NYWIO	WVRQAPGQGLEWM	GEILPGSGSTEY	TENFKDRVT	MT	204
			CDR1		CDR2				
Evans h5G1.1	81	MELSSLRSEDTAVYYC	AR	YFFGSSPNWYFDV	WGQGLTV	VSS		122	
'149 SEQ ID NO: 2	205	MELSSLRSEDTAVYYC	AR	YFFGSSPNWYFDV	WGQGLTV	VSS		246	
			CDR3						



(*Id.*, 44:4-14 (Example 11 (12)); EX1003, ¶¶86-88.) All nine constructs disclose the identical heavy chain CDR3 sequence of SEQ ID NO:2 of claim 1. (EX1003, ¶86, Appendix A.)

**3. Bell [EX1007]**

Bell is a patent application published on September 1, 2005, and is thus prior art under 35 U.S.C. §102(b). Bell teaches that anti-C5 antibody known as “h5G1.1-mAb (eculizumab)” is a “particularly useful” treatment for PNH. (EX1007, [0052], [0082].) Bell also teaches that “[m]ethods for the preparation of” h5G1.1 “are described in” Evans (EX1005) and Thomas (EX1010), “the disclosures of which are incorporated [into Bell] in their entirety.” (EX1007, [0052]; EX1003, ¶¶89-91.)

**4. Tacken [EX1008]**

Tacken is a journal article published on Aug. 15, 2005, and is thus prior art under 35 U.S.C. §102(b). Tacken teaches that “h5G1.1-mAb” is “eculizamab [*sic*].” (EX1008, 010.) Tacken states that h5G1.1-mAb contains the “human hybrid IgG2/IgG4 constant domain,” and further cites to the Mueller 1997 reference for these domains. (*Id.*; EX1003, ¶¶92-93.)


**5. Mueller PCT [EX1009]**

Mueller PCT, published April 3, 1997, is the companion international patent application of the Mueller 1997 reference cited by Tacken. (EX1003, ¶94.) It is prior art under 35 U.S.C. §102(b). Mueller PCT discloses sequences for anti-pVCAM antibodies, including the full-length 3F4 HuG2/G4 antibody, which contains a hybrid IgG2/G4 heavy chain constant region with “the C1 and hinge regions of human IgG2 and the C2 and C3 regions of human IgG4[.]” (EX1009,


Petition for *Inter Partes* Review of  
U.S. Patent No. 9,732,149 B2

8:23-26; EX1003, ¶¶95.) Mueller PCT refers to antibodies with this IgG2/G4 constant region as “**HuG2/G4 mAb.**” (*Id.*; EX1003, ¶¶96.) Mueller PCT describes using “h5G1.1 CO12 **HuG2/G4 mAb**” and discloses the amino acid sequences for the constant regions of SEQ ID NOS:2 and 4 of claim 1:

Mueller 3F4 G2/G4 C <sub>H</sub>	1	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVFSSNFGTQT	80
'149 SEQ ID NO: 2 C <sub>H</sub>	1	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVFSSNFGTQT	80
Mueller 3F4 G2/G4 C <sub>H</sub>	81	YTCNVDPKPSNTKVDKTVERKCCVECPPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG	160
'149 SEQ ID NO: 2 C <sub>H</sub>	81	YTCNVDPKPSNTKVDKTVERKCCVECPPCAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG	160
Mueller 3F4 G2/G4 C <sub>H</sub>	161	VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIISKAKGQPREPQVYTLPPSQEEMTKN	240
'149 SEQ ID NO: 2 C <sub>H</sub>	161	VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIISKAKGQPREPQVYTLPPSQEEMTKN	240
Mueller 3F4 G2/G4 C <sub>H</sub>	241	QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKS	320
'149 SEQ ID NO: 2 C <sub>H</sub>	241	QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMEALHNHYTQKS	320
Mueller 3F4 G2/G4 C <sub>H</sub>	321	SLSLGK	326
'149 SEQ ID NO: 2 C <sub>H</sub>	321	SLSLGK	326



Mueller 3F4 C <sub>L</sub>	1	VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKH	80
'149 SEQ ID NO: 4 C <sub>L</sub>	1	VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKH	80
Mueller 3F4 C <sub>L</sub>	81	KVYACEVTHQGLSSPVTKSFNRGEC	105
'149 SEQ ID NO: 4 C <sub>L</sub>	81	KVYACEVTHQGLSSPVTKSFNRGEC	105



(EX1003, ¶¶97-99; EX1009, 054-55, 058-59.)

**B. Overview of Proposed Grounds for IPR**

**Ground 1** is based on express anticipation by Bowdish. Bowdish provides the entire eculizumab amino acid sequence through SEQ ID NOS:67 and 69 and the incorporation by reference of the heavy chain CDR3 of Evans. (EX1003, ¶¶100-09.) Specifically, Bowdish provides the framework for the humanized IgG2/G4 eculizumab antibody and incorporates by reference the 13 amino acid heavy chain CDR3 for humanized 5G1.1 that Evans discloses to complete the eculizumab sequence. Thus, Bowdish and Evans qualify as a single integrated document that discloses the exact antibody sequence recited in challenged claim 1 (SEQ ID NOS:2 and 4).

**Ground 2** is based on obviousness from combining Bowdish and Evans in view of Bell, Tacke, and Mueller PCT. (EX1003, ¶¶110-126.) As noted above, POSA would have obtained SEQ ID NOS:2 and 4 from Bowdish and Evans. A POSA would have been motivated to do so by Bell, which teaches that eculizumab is a “particularly useful” antibody for treatment of PNH, also known as “h5G1.1.” Bell, like Bowdish, points to Evans for preparation of the h5G1.1 antibody. Tacke provides additional guidance to a POSA that Alexion’s “potential product,” known both as h5G1.1 and eculizumab (*sic*), contains the IgG2/IgG4 constant region reported in the Mueller 1997 reference (also disclosed in Mueller PCT). With this

guidance, a POSA would have understood that the starting sequence used by Bowdish, having the heavy chain CDR3 of Evans, was eculizumab (SEQ ID NO:2).

**Ground 3** is based on obviousness in combining Evans and Mueller PCT in view of Bell and Tacken. (EX1003, ¶¶127-135.) This Ground combines the complete variable region sequences of SEQ ID NOS:2 and 4 taught by Evans under the name “humanized 5G1.1” with the constant regions of SEQ ID NO:2 and 4 taught by Mueller PCT. The combination of Evans and Mueller PCT is directed by Tacken, which confirms the constant region of eculizumab is the IgG2/G4 type taught by Mueller PCT, and by Bell, which directs a POSA to Evans for the variable region sequence of eculizumab to treat PNH. In addition, Mueller PCT’s disclosure of “h5G1.1 CO12 HuG2/G4” specifically taught a POSA to combine with the CO12 variable domain from Evans, resulting in an antibody that is a 100% match for SEQ ID NOS:2 and 4 as recited in challenged claim 1.


**Ground 4** is based on inherent anticipation by Bell. (EX1003, ¶¶136-141.) As discussed above and as evidenced by multiple Alexion admissions to patent offices, the eculizumab antibody with the identical amino acid sequence of claim 1 was *necessarily* the exact antibody used in the PNH clinical studies described by Bell, and enabling disclosures for the claimed sequences were in the prior art. As such, Bell inherently anticipates claim 1.

This petition is supported by the declaration of Dr. Jeffrey Ravetch, M.D., Ph.D., a renowned expert in antibody structure, modification of antibody domains, and development of therapeutic antibodies for a variety of human diseases. (*See* EX1003, ¶¶1-14, 19-20.)

### C. Ground 1: Claim 1 Is Anticipated by Bowdish


Bowdish is an Alexion patent publication that, through incorporation by reference of Evans, discloses both SEQ ID NO:2 and SEQ ID NO:4, as claimed in the '149 patent. (EX1003, ¶100.) Bowdish's SEQ ID NO:69 discloses the light chain sequence of SEQ ID NO:4 in claim 1 of the '149 patent. (EX1004, Fig. 13B; EX1003, ¶101 (comparing sequences).)

Bowdish SEQ ID NO: 69	1	MDMRVPAQLLGLLLWLRGARC	DIQMTQSPSSLSASVGDRTTTC	CGASENIYGALN	WYQQKPGKAPKLLIYGATN	LADGV	80
'149 SEQ ID NO: 4	1	-----	DIQMTQSPSSLSASVGDRTTTC	CGASENIYGALN	WYQQKPGKAPKLLIYGATN	LADGV	58
				CDR1		CDR2	
Bowdish SEQ ID NO: 69	81	PSRFSGSGSGTDFTLTIS	SLQPEDFATYYC	QNVLTPLT	FGQGTKVEIKRTVAAPS	VFIFPPSDEQLKSGTASV	VCLLN 160
'149 SEQ ID NO: 4	59	PSRFSGSGSGTDFTLTIS	SLQPEDFATYYC	QNVLTPLT	FGQGTKVEIKRTVAAPS	VFIFPPSDEQLKSGTASV	VCLLN 138
				CDR3			
Bowdish SEQ ID NO: 69	161	FYPREAKVQWKVDNALQSGNSQESVTEQDSK	STYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC				236
'149 SEQ ID NO: 4	139	FYPREAKVQWKVDNALQSGNSQESVTEQDSK	STYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC				214






In addition, Bowdish explains that it created SEQ ID NO:67 from a starting heavy chain sequence that is identical to SEQ ID NO:2. Bowdish's SEQ ID NO:67 discloses all elements of the heavy chain sequence of SEQ ID NO:2 in claim 1, with the exception of the 13 amino acid "native CDR3" of "5G1.1" within SEQ ID NO:2. (EX1004, Fig. 13A & [0191]; EX1003, ¶102.) Bowdish explains that the "native CDR3" has been replaced with a TPO mimetic peptide and identifies the sequence of that peptide. (EX1004, Fig. 13A & [0191]; EX1003, ¶102.) Critically, Bowdish identifies the Evans U.S. Application Ser. No. 08/487,283 (published in 2002 as Evans '245 patent (*see* EX1005, 001)) as disclosing the "native CDR3" and incorporates the Evans application by reference. (*See* EX1004 [0191]; EX1003, ¶¶100, 102.) Accordingly, Bowdish identifies the heavy chain sequence that had the "native CDR3" before it was replaced with the TPO peptide's HCDR3:



(EX1003, ¶102.) In other words, the original heavy chain of Bowdish's 5G1.1 antibody contained Evans' "native CDR3," YFFGSSPNWYFDV, before it was replaced with the TPO mimetic peptide, LPIEGPTLRQWLAARAPV, as shown in SEQ ID NO:67. (EX1003, ¶103; EX1004 [0191]; EX1005, Fig. 19, 43:6-14, 43:61-45:4.) Accordingly, the original heavy chain has the identical sequence as SEQ ID NO:2 of claim 1.

Bowdish SEQ ID NO: 67	1	MKWSWVILFLLSVTAGVHSQVQLVQSGAEVKKPGASVKVSCKASGYIFS	NYWIQWVRQAPGQGLEWMGEILPGSGSTEYT	80
'149 SEQ ID NO: 2	1	-----QVQLVQSGAEVKKPGASVKVSCKASGYIFS	NYWIQWVRQAPGQGLEWMGEILPGSGSTEYT	61
		Original Evans CDR3 in starting 5G1.1	CDR1	CDR2
Bowdish SEQ ID NO: 67	81	ENFKDRVMTTRDTSTSTVYMESSLRSED	TAVYYCARYFFGSSPNWYFDVWGQGLT	160
'149 SEQ ID NO: 2	62	ENFKDRVMTTRDTSTSTVYMESSLRSED	TAVYYCARYFFGSSPNWYFDVWGQGLT	141
		CDR2	CDR3	
Bowdish SEQ ID NO: 67	161	ESTAALGCLVKDYFPEPVTVSWNSGALT	SGVHTFPAVLQSSGLYSLSSVTVPSSN	240
'149 SEQ ID NO: 2	142	ESTAALGCLVKDYFPEPVTVSWNSGALT	SGVHTFPAVLQSSGLYSLSSVTVPSSN	221
Bowdish SEQ ID NO: 67	241	RKCCVECPPCPAPPVAGPSVFLFPPKPKD	TLNISRTPEVTCVVVDVSQEDPEVQFN	320
'149 SEQ ID NO: 2	222	RKCCVECPPCPAPPVAGPSVFLFPPKPKD	TLNISRTPEVTCVVVDVSQEDPEVQFN	301
Bowdish SEQ ID NO: 67	321	RVVSVLTVLHQDWLNGKEYKCKVSNKGLP	SSIEKTI	400
'149 SEQ ID NO: 2	302	RVVSVLTVLHQDWLNGKEYKCKVSNKGLP	SSIEKTI	381
Bowdish SEQ ID NO: 67	401	WESNGQPENNYKTTTPVLDSDGSFFLYS	RSLTVDKSRWQEGNVFSCSVMHEALHN	467
'149 SEQ ID NO: 2	382	WESNGQPENNYKTTTPVLDSDGSFFLYS	RSLTVDKSRWQEGNVFSCSVMHEALHN	448



(EX1003, ¶103.) There can be no doubt that the 5G1.1 sequences taught in Evans encode antibodies that bind C5. (EX1005, Cover (Title), 7:60-64, 9:44-45, 143:22-144:14, Fig. 8, Claim 19; *see also* EX1022, 16:10-12; EX1003, ¶104.) Bowdish's disclosure thus anticipates claim 1.

A POSA following Bowdish's incorporation of Evans would have no difficulty immediately identifying the sequence Bowdish refers to as "the native CDR3." Evans' Example 11 teaches the construction of recombinant antibodies using the heavy and light chain CDRs of the 5G1.1 antibody. (EX1005, 42:56-45:33; EX1003, ¶104.) In all, Evans' Example 11 provides eighteen constructs of "recombinant mAb-encoding DNAs." Of these, nine provide humanized single-chain variable domain structures ("scFvs") which correspond to the V<sub>H</sub> and V<sub>L</sub> domains of an antibody joined by a short peptide linker and starting with the "MA" leader sequence. (EX1005, 42:56-45:33; EX1003, ¶¶104-106; EX1054, 017, Fig. 6.) Importantly, the *identical* HCDR3 sequence is used in *every one* of these examples. (EX1005, 9:65-10:20, 42:56-45:33, 143:22-144:14, Figs. 18-19, Claim 19; EX1003, ¶107, Appendix A.) This is not surprising, since the CDR regions determine binding to target (here, C5), and are a fundamental component of the uniqueness of a particular antibody such as 5G1.1. (EX1003, ¶107.)

Bowdish's express incorporation by reference of Evans is operative to bring the entire disclosure of Evans within Bowdish "as if it were explicitly contained therein." See *Paice LLC v. Ford Motor Co.*, 881 F.3d 894, 906 (Fed. Cir. 2018). The disclosure in Bowdish specifically incorporates Evans for "[c]onstruction of 5G1.1." (EX1004, [0191].) That is, Bowdish identifies specifically what material from Evans is being incorporated, and expressly incorporates those teachings

without qualification. Accordingly, Bowdish and Evans must be treated as an integrated single reference for anticipation purposes. *Paice*, 881 F.3d at 906-07.

The disclosure of Bowdish and Evans as a single integrated document is also enabling. It does not matter whether either of the Bowdish or Evans inventors, on their own, actually made the assembled sequence of eculizumab. *See Schering Corp. v. Geneva Pharms., Inc.*, 339 F.3d 1373, 1380-81 (Fed. Cir. 2003) (“A reference may enable one of skill in the art to make and use a compound even if the author or inventor did not actually make or reduce to practice that subject matter.”). It only matters that the Bowdish and Evans integrated document discloses sufficient information to make eculizumab. *Id.*; *see also Novo Nordisk Pharms., Inc. v. Bio-Tech. Gen. Corp.*, 424 F.3d 1347, 1356 (Fed. Cir. 2005) (reference disclosed production of hGH protein in an enabling manner because it discusses “particular materials and a particular methodology” which, in combination with “standard recombinant DNA techniques” known to a POSA, could be used to produce the protein.). (*See also* EX1003, ¶¶108-109.)

**D. Ground 2: Claim 1 Is Obvious Over Bowdish and Evans in view of Bell, Tacke, and Mueller PCT**

Separate from the anticipation-based Ground 1, Bowdish and Evans also render claim 1 obvious in view of the prior art. As noted above, Bowdish discloses the complete sequence of the light chain SEQ ID NO:4. Bowdish further incorporates Evans by reference for construction of 5G1.1, and for the heavy chain

states that its TPO mimetic peptide graft “has been transplanted into the heavy chain CDR3” of “antibody framework 5G1.1.” (EX1004, [0191].) Thus, as the Board previously concluded, “Bowdish’s disclosed starting 5G1.1 antibody is disclosed to be identical to the claimed anti-C5 antibody.” (EX1024, 036; EX1003, ¶110.)

Bowdish provides express motivation to combine its antibody framework 5G1.1 with Evans’ HCDR3 to arrive at Bowdish’s starting antibody 5G1.1, which consists of both SEQ ID NO:2 and SEQ ID NO:4, as claimed in the ’149 patent. (*See supra* VIII.C; EX1003, ¶111.) This anticipating disclosure strongly supports the obviousness of SEQ ID NOS:2 and 4 in view of the prior art. *See In re McDaniel*, 293 F.3d 1379, 1385 (Fed. Cir. 2002) (“anticipation is the epitome of obviousness.” (citation omitted)).

In addition, a POSA would have been aware of the teachings of Bell, Tacke, and Mueller PCT, which also provide motivation to combine Bowdish and Evans. These references further provide a reasonable expectation of success in obtaining the antibody of claim 1. (EX1003, ¶112.)

Bell teaches that eculizumab, also referred to as h5G1.1, had been successful in the treatment of PNH, and expressly incorporates Evans for preparing h5G1.1. Bell discloses that a “particularly useful” treatment for PNH is the anti-C5 antibody known as “h5G1.1-mAb (eculizumab).” (EX1007, [0052], [0082]; EX1003, ¶113.) As Bell explains, by 2005 “[t]he antibody h5G1.1” carried the “tradename

eculizumab.” (EX1007, [0052].) Bell provides detailed clinical trial results showing the successful treatment of PNH in humans using eculizumab, stating that eculizumab successfully “protected PNH type III [red blood cells] from complement-mediated lysis, prolonging the cells survival.” (EX1007, [0083].) These definitive clinical data would have more than motivated a POSA to obtain the structure of eculizumab. (EX1003, ¶113.) Although Bell’s disclosure does not include the exact amino sequence of eculizumab, Bell teaches that the antibody h5G1.1 *is* eculizumab, and that “methods for the preparation of” h5G1.1 “are described in” Evans (EX1005) and Thomas (EX1010), both of which are incorporated into Bell in their entirety. (EX1007, [0052].) Based on Bell’s reference to Evans for h5G1.1, and Evans’ disclosure of humanized scFv sequences (*see supra* VIII.C), a POSA would have understood that Evans contains the variable region sequences for eculizumab. (EX1003, ¶114.) And as discussed further below, a POSA would not have wrongly concluded from Bell’s mere citation to Thomas that the eculizumab disclosed in Bell would have an IgG4 isotype as discussed in the Thomas reference. (*See infra*; EX1003, ¶¶114, 123, 140.)


Further, a POSA looking to obtain the amino acid sequences for h5G1.1 (eculizumab) would have easily found Bowdish and considered it to be analogous art to Bell and to the field of the challenged patent, because it provides express teachings about the structure of the antibody “5G1.1,” identifies “Alexion

Pharmaceuticals” as the inventors’ addressee, and cites to the same Evans patent as does Bell for the structure of 5G1.1. (EX1004, Cover, [0191]; EX1003, ¶115; *see supra* VIII.C.) These links are more than sufficient to meet the standard for analogous art. *See Unwired Planet, LLC v. Google Inc.*, 841 F.3d 995, 1000-01 (Fed. Cir. 2016); *In re GPAC Inc.*, 57 F.3d 1573, 1577-79 (Fed. Cir. 1995).

Although Bowdish calls its antibody framework “5G1.1,” a POSA would have understood that it is referring to h5G1.1 based on a comparison of Bowdish’s and Evans’ variable region sequences. (EX1003, ¶116.) Bowdish’s SEQ ID NOS:67 and 69 disclose the sequences of “5G1.1” antibody framework, into which only the HCDR3 was replaced for the TPO mimetic peptide graft. (*See* EX1004, Figs. 13A & 13B.) A routine comparison of these sequences with Evans’ constructs in Example 11 would have quickly revealed that Evans’ SEQ ID NO:20 is identical to the variable regions in Bowdish’s SEQ ID NOS:69 & 67, except for the HCDR3 sequence:

Petition for *Inter Partes* Review of  
U.S. Patent No. 9,732,149 B2

Bowdish SEQ ID NO: 69	1	DIQMTQSPSSLSASVGDRVTITCGASENIYGALN	WYQ	KPKAPKLLIYGATNLADGVPSRFGSGSGTDFTLTIS	80
Evans h5G1.1	1	DIQMTQSPSSLSASVGDRVTITCGASENIYGALN	WYQ	KPKAPKLLIYGATNLADGVPSRFGSGSGTDFTLTIS	80
			CDR1	CDR2	
Bowdish SEQ ID NO: 69	81	EDFATYYCQNVLTPLT	FGQ	GTKVEIKRT	109
Evans h5G1.1	81	EDFATYYCQNVLTPLT	FGQ	GTKVEIKRTGGGGSGGGSGGGGS	124
			CDR3		
Bowdish SEQ ID NO: 67	1	QVQLVQSGAEVKKPGASVKV	CSKASYIFSN	YIWQVVRQAPGQGLEWMGEILPGSGSTEY	80
Evans h5G1.1	125	QVQLVQSGAEVKKPGASVKV	CSKASYIFSN	YIWQVVRQAPGQGLEWMGEILPGSGSTEY	204
			CDR1	CDR2	
Bowdish SEQ ID NO: 67	81	MELSSLRSEDTAVYYCAR	P	IEGPTLRQWLAA	127
Evans h5G1.1	205	MELSSLRSEDTAVYYCAR	Y	FFGSSP---NWY---FDV	246
			CDR3		



(EX1003, ¶116.) Evans’ SEQ ID NO:20 is designated “*humanized*” 5G1.1 scFv. Further, since Bowdish used an “anti-human IgG” in a binding assay to detect 5G1.1, it would have been evident to a POSA that Bowdish discloses humanized 5G1.1. (EX1003, ¶¶80, 117; EX1004, [0192].) Thus, a POSA would have understood that Bowdish’s antibody framework sequences in SEQ ID NOS:67 and 69, including the constant region sequences, are indeed humanized 5G1.1 (*i.e.*, h5G1.1). (EX1003, ¶117.)

The Tackén reference would have further confirmed that Bowdish contains the desired constant regions of eculizumab. First, Tackén is yet another reference that equates h5G1.1 with eculizumab. (EX1008, 010; *see supra* V.D.) Second and



critically, Tacke teaches that eculizumab contains an IgG2/IgG4 constant region that is “the same” as that disclosed in Tacke’s reference 17, which is the Mueller 1997 article.


**Recombinant antibodies**

The humanized antihuman DC-SIGN antibody hD1V1G2/G4 (hD1) was generated by complementarity determining region (CDR) grafting of AZN-D1 hypervariable domains into human framework regions. The humanized variable heavy and variable light regions were then genetically fused with a human hybrid IgG2/IgG4 constant domain<sup>17</sup> and a human kappa chain constant domain, respectively. This construct was cloned into a mammalian expression vector and the final construct transfected into NSO cells. Stable transfectants were obtained using glutamine synthetase (GS) selection (Lonza Biologics, Portsmouth, NH). Supernatants containing hD1 were purified over a protein A column. An isotype control antibody, h5G1.1-mAb (5G1.1, eculizumab; Alexion Pharmaceuticals) containing the same IgG2/IgG4 constant region, is specific for the human terminal complement protein C5.<sup>19</sup>


(EX1008, 011 (citing EX1006); EX1003, ¶118.) Mueller PCT, the companion patent application for Mueller 1997, expressly discloses the full amino acid sequence for the IgG2/IgG4 constant domain heavy chain used in the “h5G1.1 HuG2/G4” antibody. (EX1009, 014, 058-59, 097; EX1003, ¶119.) A routine alignment of the IgG2/G4 constant domain heavy chain from Mueller PCT and Bowdish would have immediately confirmed that the antibody disclosed in Bowdish has *precisely* the sequence of eculizumab:

Petition for *Inter Partes* Review of  
U.S. Patent No. 9,732,149 B2

Bowdish SEQ ID NO: 67 C <sub>H</sub>	1	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTWNSGALTSGLVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQT	80
Mueller 3F4 G2/G4 C <sub>H</sub>	1	ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTWNSGALTSGLVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQT	80
Bowdish SEQ ID NO: 67 C <sub>H</sub>	81	YTCNVDHKPSNTKVDKTVVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDG	160
Mueller 3F4 G2/G4 C <sub>H</sub>	81	YTCNVDHKPSNTKVDKTVVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDG	160
Bowdish SEQ ID NO: 67 C <sub>H</sub>	161	VEVHNAKTKPREEQFNSTYRVVSVLTVTLHQDWLNGKEYKCKVSNKGLPSSIEKTIISKAKGQPREPQVYTLPPSQEEMTKN	240
Mueller 3F4 G2/G4 C <sub>H</sub>	161	VEVHNAKTKPREEQFNSTYRVVSVLTVTLHQDWLNGKEYKCKVSNKGLPSSIEKTIISKAKGQPREPQVYTLPPSQEEMTKN	240
Bowdish SEQ ID NO: 67 C <sub>H</sub>	241	QVSLTCLVKGFPYSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCVMHEALHNHYTQKSL	320
Mueller 3F4 G2/G4 C <sub>H</sub>	241	QVSLTCLVKGFPYSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCVMHEALHNHYTQKSL	320
Bowdish SEQ ID NO: 67 C <sub>H</sub>	321	SLSLGK	326
Mueller 3F4 G2/G4 C <sub>H</sub>	321	SLSLGK	326



(EX1003, ¶¶119-120.) Just as easily, a POSA in March 2007 would have readily confirmed that Bowdish’s starting 5G1.1 antibody had the desired IgG2/G4 constant regions as opposed to pure IgG2 or IgG4 constant regions by running Bowdish’s 5G1.1 antibody through a protein sequence search. (EX1003, ¶121; *see also* EX1033, 005; EX1037, 005.) With this confirmation in hand, a POSA would have known to swap back into Bowdish’s SEQ ID NO:67 the thirteen amino acid heavy chain CDR3 disclosed throughout Evans – as shown below:



(EX1003, ¶121.)

Tacken, like Bowdish, is analogous art to Bell and to the field of the challenged patent. Tacken is from the same field of study (humanized antibodies, including eculizumab) and is pertinent to the issue of the structure of eculizumab, which Tacken expressly identifies and describes as an anti-C5 antibody and Alexion's "potential product." (EX1008, 010-11; EX1003, ¶122.) A POSA seeking the sequence of eculizumab would have relied on Tacken, and its clear teaching from 2005 that eculizumab has an IgG2/IgG4 constant domain. (EX1003, ¶122.) A POSA reading Tacken would also have understood that Thomas—which was

Petition for *Inter Partes* Review of  
U.S. Patent No. 9,732,149 B2

published in 1996 and pre-dates Mueller PCT—discloses only an IgG4 isoform of 5G1.1, and was thus not eculizumab. (EX1010, 013, EX1003, ¶123.) Moreover, Mueller PCT is analogous art to Bell, Bowdish, Evans, and Tacken, and to the field of the challenged patent, because like those references it is concerned with recombinant antibodies, expressly recites 5G1.1, is associated with Alexion Pharmaceuticals, and has Alexion scientist Mark Evans identified as an inventor on both Evans and Mueller PCT. (EX1006, Cover, 12:19-27; EX1005, Cover; EX1003, ¶124.)

The teachings of the prior art cited in this Ground provide a direct route to the sequence of eculizumab that renders challenged claim 1 obvious. (EX1003, ¶125.) A POSA would have been strongly motivated by Bell to obtain the sequence of eculizumab. Indeed, Bell is just one of many references in the prior art which taught that eculizumab was a useful treatment for PNH. (*See* EX1011; EX1013; EX1012; EX1014; EX1015; EX1003, ¶125.) A POSA further would have been informed by Tacken as to important details regarding the structure of eculizumab. From the combined teaching of Bowdish and Evans, a POSA could immediately confirm the correctness of the constant region against the teachings of Mueller PCT. (EX1003, ¶125.)

A POSA also would have had a reasonable expectation of success in assembling SEQ ID NOS:2 and 4 recited in challenged claim 1, since the prior art

already confirmed each of the details necessary to create the heavy and light chains of the antibody. (EX1003, ¶126.) A POSA would have understood how to make an anti-C5 antibody with SEQ ID NOS:2 and 4 using the teachings of Bowdish and Evans and standard, well-known molecular biology methods. (EX1004, [0069]-[0070], [0131]; EX1005, 45:24-33; EX1003, ¶126.)

**E. Ground 3: Claim 1 Is Obvious Over Evans and Mueller PCT in view of Bell and Tacken**

A POSA would also have been directed by Bell and Tacken to Evans and Mueller PCT, without the need for Bowdish. As explained in Ground 2, a POSA would have been strongly motivated by Bell to obtain the amino acid sequence of the anti-C5 antibody eculizumab—the subject matter of Claim 1. Bell points directly to Evans and Thomas for this information and incorporates both by reference. (*See supra* VIII.D; EX1003, ¶127.) A POSA examining Evans, entitled “C5-specific Antibodies for the Treatment of Inflammatory Diseases” would readily understand that it teaches the critical CDR sequences for the heavy and light chains of the original mouse antibody 5G1.1, which binds C5, as well as variable domain sequences for humanized forms of 5G1.1. (EX1005, 1:1-3, 9:65-10:20, 42:56-45:23, Figs. 18-19, Claim 19; EX1003, ¶¶128-129.)


Evans’ Example 11 teaches the construction of recombinant antibodies using the heavy and light chain CDRs of the 5G1.1 antibody. (EX1005, 42:56-45:33; EX1003, ¶128; *see supra* VIII.D.) In all, Evans’ Example 11 provides eighteen

“recombinant mAb-encoding DNAs” constructs. Of these, nine provide humanized single-chain variable domain structures (“scFv”) which correspond to the V<sub>H</sub> and V<sub>L</sub> domains of an antibody joined by a short peptide linker. (EX1005, 42:56-45:33; EX1003, ¶128.) Evans then explains that “one each of the various L1, L2, and L3 CDRs” and “one each of the various H1, H2, and H3 CDRs” disclosed in Example 11, assembled into “matched pairs of the variable regions (e.g. a V<sub>L</sub> and a V<sub>H</sub> region) ... may be combined with constant region domains by recombinant DNA or other methods known in the art to form full length antibodies *of the invention*.” (EX1005, 45:5-33 (emphasis added); EX1003, ¶128.)

A POSA would have been motivated to build antibodies using *each* of the sequences labeled “5G1.1.” Even if Evans does not identify the specific sequence used in eculizumab by name, it explains that *each* of the nine disclosed sequences include V<sub>H</sub> and V<sub>L</sub> domains with the CDRs of 5G1.1. (EX1005, 42:56-45:33; EX1003, ¶¶129-130.) Bell points to Evans for its teaching of the structure of 5G1.1, thus a POSA would have known to try any of these sequences. *See Merck & Co. v. Biocraft Lab ’ys, Inc.*, 874 F.2d 804, 807 (Fed. Cir. 1989) (“That the [asserted prior art] discloses a multitude of effective combinations does not render any particular formulation less obvious.”). When, as here, there are a “finite number of identified, predictable solutions,” a POSA has good reason to pursue them and the resulting

combinations are obvious ones. *See KSR Int'l Co. v. Teleflex, Inc.*, 550 U.S. 398, 421 (2007). (EX1003, ¶130.)


Even if a POSA wished to prioritize among the nine constructs providing a humanized V<sub>H</sub> and V<sub>L</sub> disclosed in Evans' Example 11 to choose, Mueller PCT would have guided POSA to the sequence in part 12 of Example 11, identified as "CO12." (*See* EX1005, 44:4-14; EX1009, 014; EX1003, ¶131.) The only 5G1.1 discussed in Mueller PCT is referred to as "h5G1.1 **CO12** HuG2/G4," thus a POSA would have been particularly motivated to assemble a full length G2/G4 antibody using the variable region employed in the CO12 example of Evans. (EX1009, 014; EX1003, ¶131 (emphasis added).) This assembly with the constant G2/G4 regions of Mueller PCT and variable regions of Evans results in the claimed sequences:




(EX1003, ¶131.) The resulting antibody is a perfect match to SEQ ID NOS:2 and 4 recited in challenged claim 1, which correspond to eculizumab (EX1003, ¶132):

Petition for *Inter Partes* Review of  
U.S. Patent No. 9,732,149 B2

Evans + Mueller	1	QVQLVQSGAEVKKPGASVKVSKASGYIFSNIYQWVRQAPGGLEWMGEILPGSGSTEYTENFKDRVTMTTRDTSTSTVY	80
'149 SEQ ID NO: 2	1	QVQLVQSGAEVKKPGASVKVSKASGYIFSNIYQWVRQAPGGLEWMGEILPGSGSTEYTENFKDRVTMTTRDTSTSTVY	80
Evans + Mueller	81	MELSSLRSEDATVYYCARYFFGSSPNWYFDVWGQGLTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT	160
'149 SEQ ID NO: 2	81	MELSSLRSEDATVYYCARYFFGSSPNWYFDVWGQGLTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT	160
Evans + Mueller	161	VSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCAPPVAGPS	240
'149 SEQ ID NO: 2	161	VSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCAPPVAGPS	240
Evans + Mueller	241	VFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVSVLTVLHQDWLNGKEY	320
'149 SEQ ID NO: 2	241	VFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVSVLTVLHQDWLNGKEY	320
Evans + Mueller	321	KCKVSNKGLPSSIEKTIKAKGQPREPQVYITLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLD	400
'149 SEQ ID NO: 2	321	KCKVSNKGLPSSIEKTIKAKGQPREPQVYITLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLD	400
Evans + Mueller	401	SDGSFFLYSRLTVDKSRWQEGNVFSCVMHEALHNHYTQKSLSLSLGK	448
'149 SEQ ID NO: 2	401	SDGSFFLYSRLTVDKSRWQEGNVFSCVMHEALHNHYTQKSLSLSLGK	448



Evans + Mueller	1	DIQMTQSPSSLSASVGDRTITCGASENIYGALNWIYQKPKGAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISLQP	80
'149 SEQ ID NO: 4	1	DIQMTQSPSSLSASVGDRTITCGASENIYGALNWIYQKPKGAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISLQP	80
Evans + Mueller	81	EDFATYYCQNVLTPLTFGGGTKVEIKRTVAAPSVEIFPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ	160
'149 SEQ ID NO: 4	81	EDFATYYCQNVLTPLTFGGGTKVEIKRTVAAPSVEIFPPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ	160
Evans + Mueller	161	ESVTEQDSKSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC	214
'149 SEQ ID NO: 4	161	ESVTEQDSKSTYLSSTLTLSKADYKHKVYACEVTHQGLSSPVTKSFNRGEC	214





Also as explained in Ground 2, Tacke specifically teaches that eculizumab has an IgG2/IgG4 constant region, and refers to the Mueller 1997 reference for this point. (*See supra* VIII.D.) A POSA would thus have been motivated by the express teachings of Tacke to create an antibody using the variable domain for 5G1.1 disclosed in Evans and the constant region discussed in Mueller 1997 and expressly taught in Mueller PCT. (*See supra* VIII.D.) Indeed, the same disclosure in Evans providing instructions for how to combine 5G1.1 variable regions with constant region domains to form a full-length antibody *expressly* suggests that it is “[p]articularly preferred” to use “a mixture of constant domains from IgGs of various subtypes” – exactly like the IgG2/IgG4 disclosure of Tacke and Mueller PCT. (EX1005, 45:29-33; EX1003, ¶133.)

Although these disclosures provided ample motivation to a POSA to use Evans and Mueller PCT to prepare the amino acid sequences for h5G1.1 IgG2/IgG4 that are recited in challenged claim 1, the art provides still further motivation. The Mueller 1997 reference associated with Mueller PCT provides *general* motivation to convert IgG4 isotype antibodies to the “HuG2/G4 design” in any human antibody intended for therapeutic use “where elimination of FcR binding and C activation may be desirable.” (EX1006, 016; EX1003, ¶¶48, 134.) A POSA would have immediately recognized these benefits as useful in the context of a therapeutic antibody intended for use to block part of the complement system. (EX1003, ¶134.)

Thus, a POSA would have been motivated to use the humanized 5G1.1 variable domains of Evans and combine them with constant regions from Mueller PCT to make the antibody of claim 1. (*Id.*) Still other disclosures in the prior art similarly taught that antibodies with hybrid IgG2/IgG4 constant regions conferred benefits such as reduced inflammation and activation of the complement system. (EX1021; EX1003, ¶134.)

The same disclosures would also have provided a POSA with a complete expectation of success, since a POSA would know from Tacke that such assemblies had already been made to form eculizumab, which had itself already been validated as a PNH treatment as shown in Bell and other studies. *See KSR Int'l*, 550 U.S. at 416 (“combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results”); (EX1003, ¶135).

**F. Ground 4: Claim 1 Is Anticipated by Bell**

As discussed above, Bell discloses clinical trials that show the utility of using eculizumab as a treatment for PNH. (*See supra* V.B.) Indeed, Bell is just one of several references that discloses the same eleven patient trial in which eculizumab was given to transfusion-dependent PNH patients; Hillmen 2004 discloses initial results while Bell and Hill 2005 supplement the record with longer-term follow up data. (*Id.*; EX1011; EX1013; EX1003, ¶136.)

**1. Bell Necessarily Discloses SEQ ID NOS:2 and 4, the Anti-C5 Antibody Known as Eculizumab**

It is equally clear from Bell that patients were treated with the antibody known as eculizumab. And as noted above, there is no doubt that disclosure of eculizumab, by name, unambiguously refers to the h5G1.1 IgG2/IgG4 molecule that is exactly identical to the subject matter of challenged claim 1. Even though appreciation of an inherent disclosure by a POSA at the time of the disclosure is not required, *Schering Corp. v. Geneva Pharmaceuticals, Inc.*, 339 F.3d 1373, 1377 (Fed. Cir. 2003), a POSA would have known that eculizumab has the same sequence as the sequences in claim 1, SEQ ID NOS:2 and 4. As explained above in Grounds 1-3, before 2007 a POSA would have understood the amino acid sequence of eculizumab. The teachings of at least Bowdish and Evans, and Evans and Mueller PCT, all in view of Tacke, provided POSA with multiple direct routes to that sequence. (*See supra* VIII.C-E.) Alexion sought to claim through the '149 patent what it says is the “novel” sequence of eculizumab, but because the prior art necessarily disclosed eculizumab, Alexion cannot obtain a patent on “the identification and characterization of a prior art material.” *In re Crish*, 393 F.3d 1253, 1258 (Fed. Cir. 2004) (ruling specific nucleotide sequence of previously known plasmid unpatentable).

Indeed, Alexion cannot dispute these facts, because Alexion has admitted to the Patent Office that the C5-binding antibody used in the study described by Bell

*was necessarily* eculizumab, which has the same structure of the antibody of claim

1. For example, the 11 patient Phase 2 pilot study (“C02-001”) and the extensions of that study (“E02-001” and “X03-001”) were submitted by Alexion during prosecution with the statement that “the antibody (eculizumab) used in each of the studies ... contained the heavy and light chain sequences of SEQ ID NOs: 2 and 4.”

(See EX1002, 1277-80, ¶¶5-6; *see also id.*, 1272; EX1003, ¶137.)

Alexion reconfirmed these admissions in the previously-instituted Amgen IPR, where it admitted to this Board that “it is known today that SOLIRIS® as used in these studies had the claimed sequence of SEQ ID NOs: 2 and 4.” (EX1025, 039 (emphasis omitted); EX1003, ¶138.) Of course, it is not necessary for inherent anticipation for a POSA to have appreciated the precise amino acid sequence of eculizumab at the time of Bell’s publication. *Schering*, 339 F.3d at 1377. But Bell inherently anticipates because (1) Alexion admits that the “eculizumab” disclosed in Bell was *necessarily* of the same sequence as recited by challenged claim 1; and (2) the prior art available to a POSA fully enabled the preparation of eculizumab as of no later than the 2005 (the publication date of Tacke). (EX1003, ¶139.)

Alexion’s admissions on this subject are binding, disposing of the need for the Board to engage in factfinding on this issue. *See Southwall Techs., Inc. v. Cardinal IG Co.*, 54 F.3d 1570, 1578 (Fed. Cir. 1995) (“A patentee may not proffer an interpretation for the purposes of litigation that would alter the indisputable public

Petition for *Inter Partes* Review of  
U.S. Patent No. 9,732,149 B2

record consisting of the claims, the specification and the prosecution history[.]”  
(citation omitted)); *see also Gillette Co. v. Energizer Holdings, Inc.*, 405 F.3d 1367,  
1374 (Fed. Cir. 2005) (holding party to “blatant admission” in argument made to  
EPO); *Apple Inc. v. Motorola, Inc.*, 757 F.3d 1286, 1312-13 (Fed. Cir. 2014),  
*overruled on other grounds sub nom. Williamson v. Citrix Online, LLC*, 792 F.3d  
1339 (Fed. Cir. 2015).

Alexion has previously argued that Bell does not *necessarily* disclose SEQ ID  
NOS:2 and 4 (eculizumab), because of ambiguity as to whether “eculizumab”  
referred to a version of the antibody in its IgG4 form, as originally reported in  
Thomas 1996. (See EX1010; EX1003, ¶140.) But the prior art plainly dispels this  
manufactured ambiguity. No prior art reference anywhere states that “eculizumab”  
has an IgG4 isotype. On the contrary, the only disclosure in the prior art as to the  
constant domain structure of “eculizumab” is Tacke, which unambiguously states  
that it has the IgG2/IgG4 structure. (EX1008, 010-11; EX1003, ¶140; *see also supra*  
V.D.) This is not a question of “probabilities or possibilities.” *MEHL/Biophile Int’l*  
*Corp. v. Milgraum*, 192 F.3d 1362, 1365 (Fed. Cir. 1999) (citations omitted).  
Instead, as Tacke makes clear, Bell’s disclosure of the PNH clinical trial of  
eculizumab *necessarily* discloses SEQ ID NOS:2 and 4 of challenged claim 1.  
(EX1003, ¶140.)

**2. The Prior Art Enabled the Eculizumab Sequences Inherently Disclosed in Bell**

The disclosures in the inherently anticipating Bell reference also meet the relevant test for enablement. To the extent Alexion argues that the reference is not, by itself, “enabling” for the amino acid sequence of eculizumab, this argument is unavailing. The prior art can and does provide sufficient information for a POSA to make the claimed subject matter that is inherently disclosed. (*See supra* VIII.C); *Schering*, 339 F.3d at 1380-81 (prior art is enabling if it discloses sufficient information to make the claimed subject matter). In this context, the art includes not just the inherently anticipating reference in isolation, but also a POSA’s knowledge of the relevant art. *See In re Elsner*, 381 F.3d 1125, 1128 (Fed. Cir. 2004) (proper test is “whether [a POSA] could take the description of the invention in the printed publication *and combine it with his own knowledge of the particular art* and from this combination be put in possession of the invention” (emphasis added) (citation omitted)); *see also In re Donohue*, 766 F.2d 531, 533 (Fed. Cir. 1985) (subject matter disclosed “if one of ordinary skill in the art could have combined the publication’s description of the invention with his own knowledge to make the claimed invention.”).

As explained throughout Grounds 1-3 above, the prior art provided enabling disclosures for creation of the same antibody (eculizumab) that is claimed in challenged claim 1. (*See supra* VIII.C-E; EX1003, ¶141.) A POSA in possession

of the relevant prior art would have had multiple clear paths to making the exact antibody that is recited by challenged claim 1. Thus, the mere use of the word “eculizumab” by Bell provides an anticipating disclosure, because before 2007 a POSA had “the ability to make” eculizumab, and thus was in possession of the subject matter of challenged claim 1. *See In re Gleave*, 560 F.3d 1331, 1337 (Fed. Cir. 2009).

#### **IX. NO SECONDARY CONSIDERATIONS OF NONOBVIOUSNESS**

There are no secondary considerations that would weigh against the strong case of obviousness set forth in Grounds 2 and 3. (*See* EX1003, ¶¶142-147.) Secondary considerations must be tied to what is *novel* in the claim, indeed any secondary considerations evidence that is not “both claimed *and* novel in the claim” cannot be said to have a nexus to the claimed invention. *In re Kao*, 639 F.3d 1057, 1068 (Fed. Cir. 2011) (emphasis added and omitted).

To the extent Alexion will argue that secondary considerations evidence can be derived from commercial success of its drug Soliris (the brand name of eculizumab), any such evidence must fail as evidence of nonobviousness because the use of eculizumab as a treatment for PNH was *indisputably* in the prior art and thus not novel in the claim. (EX1003, ¶¶142-143.) Several prior art publications expressly disclosed the utility of eculizumab as a treatment for PNH, including the Bell, Hillmen 2004, and Hill 2005 references. (*See supra* V.A and VIII.F.) *See*

Petition for *Inter Partes* Review of  
U.S. Patent No. 9,732,149 B2

*Ormco Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1312 (Fed. Cir. 2006) (“if the feature that creates the commercial success was known in the prior art, the success is not pertinent.”). Similarly, the fact that eculizumab was not commercially approved as a treatment for PNH until March 2007 is of no moment to the secondary considerations analysis, because the use of eculizumab as a PNH therapy is undisputed prior art to the ’149 patent. *See Novartis AG v. Torrent Pharms. Ltd.*, 853 F.3d 1316, 1330-31 (Fed. Cir. 2017) (finding the fact that Patent Owner’s drug was the first to receive FDA commercial marketing approval for solid oral treatment for multiple sclerosis was not probative of nonobviousness when “[t]he treatment of multiple sclerosis with a solid oral composition ... was indisputably known in the prior art.”). (*See also* EX1024, 040-41.)

There is also no presumption of nexus, because challenged claim 1, which recites only an antibody sequence as a composition of matter, is not co-extensive with the *treatment* of PNH. *See Fox Factory, Inc. v. SRAM, LLC*, 944 F.3d 1366, 1373 (Fed. Cir. 2019). Indeed, any evidence based on Soliris sales must be due to the claimed invention specifically, not Alexion’s other efforts such as marketing, *and* not contributions from the prior art. *See, e.g., Prometheus Lab’ys, Inc. v. Roxane Lab’ys, Inc.*, 805 F.3d 1092, 1101 (Fed. Cir. 2015); *In re Huang*, 100 F.3d 135, 140 (Fed. Cir. 1996). Moreover, as explained above, Alexion has long identified the prior art Evans patent, not the challenged ’149 patent, with the invention of



eculizumab, and indeed sought to apply patent term extension under 35 U.S.C. § 156 for Soliris to the Evans patent. (*See supra* V.D.) Given the extensive disclosures of eculizumab sequence in the prior art, Alexion cannot establish that commercial success based on Soliris's product launch in 2007 is relevant. (EX1003, ¶143.)

Similarly, Alexion cannot argue that the sequence of eculizumab recited in challenged claim 1 solved a long-felt and art-recognized need, as required, because prior art published two to three years before the priority date of the '149 disclosed eculizumab as a treatment for PNH. Thus, judged against the priority date, as it must be, it cannot be said that as of March 2007 the long-felt need addressed by Soliris still existed. *See Nike, Inc. v. Adidas AG*, 955 F.3d 45, 55 (Fed. Cir. 2020) (finding no long-felt need existed because "other methods of minimizing waste ... had existed before the date of the invention"); *Celgene Corp. v. Peter*, 931 F.3d 1342, 1352 (Fed. Cir. 2019) (finding no long-felt need existed because "[Patent Owner] did not show that the prior art methods of controlling the distribution of hazardous drugs ... were insufficient to meet any need to control distribution of thalidomide."). (EX1003, ¶144.)

Nor is there any competent evidence of industry praise. Any industry recognition following the launch of Soliris as a beneficial therapy for the rare disease PNH has no nexus with anything inventive in challenged claim 1. As with the considerations of commercial success and long-felt need, by March 2007 there was

nothing *novel* about the use of eculizumab to treat PNH. Further, any prizes awarded to Alexion relating to the use of Soliris as a PNH treatment have no nexus because there is nothing to suggest that the prize was awarded due to anything specific to the sequence of eculizumab recited in challenged claim 1, as opposed to what was already known in the art. *See S. Ala. Med. Sci. Found. v. Gnosis S.P.A.*, 808 F.3d 823, 827 (Fed. Cir. 2015) (prize lacked nexus because it was directed to a method of treatment already known in the prior art); *see also Genentech, Inc. v. Hospira, Inc.*, 946 F.3d 1333, 1342 (Fed. Cir. 2020). (EX1003, ¶145.)

Finally, Alexion cannot rely on Petitioner’s intent to develop a biosimilar of Soliris as evidence of “copying,” because the biosimilar statutes and regulations *require* that any biosimilar of Soliris be “highly similar to the reference product.” *See* 42 U.S.C. §262(i)(2); *see also Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc.*, 25 F.4th 1354, 1374 (Fed. Cir. 2022) (“evidence of copying in the ANDA context is not probative of nonobviousness because a showing of bioequivalence is required for FDA approval.” (citation omitted)). (EX1003, ¶146.)

Petitioner reserves the right to rebut any evidence of secondary considerations that Alexion asserts in this proceeding.

## **X. THE BOARD SHOULD REACH THE MERITS OF THE PETITION**

No basis exists under either §314(a) or §325(d) for discretionary denial, as explained below.

Petition for *Inter Partes* Review of  
U.S. Patent No. 9,732,149 B2

**A. §314(a)**

The '149 patent has never been asserted in any litigation.

**B. §325(d)**

The Board assesses § 325(d) issues under the two-part *Advanced Bionics* framework: (1) whether the same or substantially the same art was previously presented to the Office, and if so (2) whether Petitioner has demonstrated that the Examiner erred in a manner material to the patentability of challenged claims. *Advanced Bionics, LLC v. Med-El Elektromedizinische Geräte GMBH*, IPR2019-01469, Paper 6 at 8 (PTAB Feb. 13, 2020) (precedential as to § III.C.5, first paragraph). Examples of “material error” could be “misapprehending or overlooking specific teachings of the relevant prior art where those teachings impact patentability of the challenged claims” or misapplying the law in a material way. *Id.* at 8-9 n.9.

This Petition should be instituted in light of the *Advanced Bionics* framework and the art and arguments presented during prosecution of the '149 patent and its child '189 patent. Part (1) of the framework is not satisfied because the Examiner did not consider critical art and arguments relied on in this Petition. To the extent certain art or arguments were considered, Part (2) is satisfied because the Examiner materially erred by overlooking specific teachings of the prior art, accepting without

challenge Alexion's incorrect characterizations of the art; and by misapplying the law with respect to secondary considerations for non-obviousness.

**1. Evaluation of Art and Arguments During '149 Prosecution**

Part (1) of the *Advanced Bionics* framework is not satisfied because the arguments and evidence presented herein were not before the Examiner during '149 prosecution, and therefore, do not constitute "the same or substantially the same prior art or arguments" under §325(d). During '149 prosecution, the Examiner rejected the claims over the Hillmen, Appel, or Wang references, and cited disclosures of Evans and Thomas for eculizumab sequence information. (EX1002, 1079-81.) Although Evans was cited in a rejection, this Petition presents that key reference in a different light. Petitioner also combines Evans with Tacke, Bell, Bowdish, and Mueller PCT, which teach the IgG2/IgG4 constant domain of eculizumab. The Examiner did not evaluate this combination or the arguments presented in this Petition regarding these references during prosecution. (*See supra* VIII.C-E.) Thus, Petitioner's arguments with respect to Evans are not the same or substantially the same as those considered by the Examiner.

Part (1) also does not apply to Tacke and Mueller PCT because they are new references that were not identified anywhere during '149 prosecution. Tacke, published in 2005, discloses that eculizumab has the IgG2/G4 constant domain. (*See supra* VIII.A.4.) Mueller PCT provides the complete sequence for IgG2/G4 constant

Petition for *Inter Partes* Review of  
U.S. Patent No. 9,732,149 B2

domain.<sup>5</sup> Grounds 2 and 3 in this Petition rely on Tacken and Mueller PCT as primary references. (*See supra* VIII.D-E.) And for Ground 4, Tacken and Mueller PCT inform the state of the art and a POSA's knowledge regarding the eculizumab sequence as of March 2007. (*See supra* VIII.F.)

Further, although Bell and U.S. 7,482,435 (parent of Bowdish) were cited in Information Disclosure Statements during prosecution, there is no evidence that these references were considered by the Examiner. The Board has consistently found that when a reference is not the basis of rejection, and merely cited in an IDS, it weighs "strongly against" exercising discretionary denial. *See, e.g., CODE200, UAB v. Bright Data Ltd.*, IPR2022-00353, Paper 8 at 10 (PTAB July 1, 2022). This is particularly true where there is a credible showing of Examiner error. *See Whitewater W. Indus., Ltd. v. Am. Wave Machs., Inc.*, IPR2022-01034, Paper 8 at 34-35 (PTAB Nov. 22, 2022); *Advanced Energy Indus. Inc. v. Reno Techs. Inc.*,

---

<sup>5</sup> Mueller PCT is not cumulative of disclosures of the Mueller 1997 article for purposes of §325(d), because Mueller PCT has the complete IgG2/G4 constant domain that is used in eculizumab, whereas Mueller 1997 does not expressly disclose the sequence for the CH3 region of the IgG2/G4 constant domain. (EX1009, 058-59; EX1006, 014.)

IPR2021-01397, Paper 7 at 7-8 (PTAB Feb. 16, 2022); *Samsung Elecs. Co. v. G+ Commc'ns, LLC*, IPR2022-01598, Paper 10 at 13 (PTAB Apr. 4, 2023).

Part (2) of *Advanced Bionics* is also satisfied with respect to Bell and Bowdish because the Examiner materially erred in overlooking specific disclosures of these references regarding the eculizumab sequence, corresponding to SEQ ID NOS:2 and 4 of challenged claim 1. In the Office Action, the Examiner rejected the claims as anticipated by Hillmen, and only focused on Evans and Thomas for eculizumab sequence information. (EX1003, ¶¶148-149.) Alexion responded, misleadingly, that “[n]either eculizumab nor its complete sequence ... was in the public domain prior to the March 15, 2007 effective filing date[.]” (EX1002, 1251; *see supra* V.D & VI.C; EX1003, ¶150.) As a result, the Examiner committed error when he accepted Alexion’s mischaracterization of the art, and failed to appreciate other pre-priority date references, such as (1) Tacke, which discloses that eculizumab contains the IgG2/G4 constant domain, (2) Mueller PCT that discloses the IgG2/G4 constant domain sequence, and (3) Bowdish, which discloses the sequence for antibody 5G1.1, including the complete sequence for IgG2/G4 constant domain. (*See supra* VIII.C-D; EX1003, ¶151.) Indeed, Tacke, Mueller PCT and Bowdish teach the very thing that the Examiner mistakenly concluded was missing from the prior art. They are also enabling prior art for Bell. Thus, the prosecution history reflects a significant gap in Examiner’s evaluation of art and arguments regarding

the known IgG2/G4 constant domain of eculizumab in the heavy chain, SEQ ID NO:2, that is recited in claim 1. (EX1003, ¶151.)

## **2. Evaluation of Art and Arguments During Prosecution of '189 Child Patent**

The prosecution record of the '189 patent also does not preclude institution of this Petition because the '189 claims are different from the '149 claim, and the Examiner materially erred in his evaluation of the asserted art and arguments during '189 prosecution.<sup>6</sup> The Board has declined to exercise denial under §325(d) over art and arguments considered during a child patent's prosecution with "separate and distinct claims" where Petitioner has shown that the Examiner erred in evaluation of

---

<sup>6</sup> To the extent that Patent Owner argues that Amgen's IPR2019-00741 raised the same art and arguments, the Board should still institute this Petition because (1) it provides different arguments based on Tacke (see, e.g., *supra* VIII.D, E; EX1003, ¶¶110-135) and additional motivations to use the IgG2/G4 constant domain (see, e.g., *supra* VIII.E; EX1003, ¶134), and (2) "the present Petitioner is different from the prior [P]etitioner." See *Medtronic Xomed, Inc. v. Neurovision Med. Prods., Inc.*, IPR2016-01405, Paper 12 at 8-9 (PTAB Dec. 29, 2016) (declining to deny institution based on prior-filed petition because arguments presented in the pending Petition "are not the same as those presented in the prior petition"). Thus, it would be "unfair to Petitioner" to exercise discretion under §325(d). *Id.*

art or arguments. *See Apple Inc. v. Seven Networks, LLC*, IPR2020-00285, Paper 10 at 28–31 (PTAB July 28, 2020) (“*Seven Networks*”) (granting institution where child patent’s “separate and distinct claims” were allowed over an IPR Petition cited in an IDS because Examiner did not provide a reason for allowance that addressed all the art or arguments); *SharkNinja Operating LLC v. iRobot Corp.*, IPR2021-00545, Paper 11 at 13-14 (PTAB Sept. 8, 2021) (although child patent’s claims “recited a number of limitations not recited by the challenged claims,” the Board did not deny under §325(d) because petitioner demonstrated that the Office erred in evaluation of the prior art). The Board should similarly decline to exercise discretionary denial here because the Examiner erred during prosecution of the ’189 patent for at least the following reasons (EX1003, ¶152):

**(a) Error 1: The Examiner Overlooked Tacken and Mueller PCT**

*First*, the Examiner materially erred in not appreciating the significance of Tacken or Mueller PCT during prosecution. Both Tacken and Mueller PCT were cited in Amgen’s three IPR petitions, all of which were submitted in an IDS during ’189 prosecution. (EX1032, 048, Nos. 4-6.) Tacken and Mueller PCT were also separately identified in an IDS. (EX1032, 027, 038.) As described above, Tacken expressly teaches that eculizumab contains the IgG2/G4 constant region, and Mueller PCT discloses that sequence. (*See supra* VIII.C.) But the Examiner did not appreciate Tacken’s or Mueller PCT’s disclosure, as evidenced by his failure to



address either reference in the Office Action or Reasons for Allowance. (EX1034; EX1035; EX1003, ¶153.) *See Seven Networks*, Paper 10 at 28–31 (granting institution because the Examiner did not provide a reason for allowance that addressed the art or arguments presented in an IPR petition listed in an IDS); *RTI Surgical, Inc. v. LifeNet Health*, IPR2019-00573, Paper 20 at 26-27 (PTAB Aug. 12, 2019) (granting institution because the Examiner did not issue a rejection based on art that was cited in an IPR petition listed in an IDS).

It is not surprising that the Examiner overlooked Tacken and its teachings because Alexion mischaracterized the literature regarding the sequence of eculizumab. (EX1003, ¶154.) In its Response to an Office Action, Alexion stated:

[T]he literature as of March 15, 2007 ... **consistently** identified “eculizumab” as the antibody described in the “Thomas” publication, ... which has a naturally-occurring “IgG4” heavy chain constant region. Accordingly, a person of ordinary skill in the art as of March 15, 2007 would have had **no doubt** that “eculizumab” was Thomas’s IgG4-isotype humanized antibody, because the pertinent literature **consistently and unambiguously** said so[.]

(EX1036, 006 (emphasis added).) Alexion went on to list several references that

purportedly referred to eculizumab as an IgG4 antibody.<sup>7</sup> But Alexion failed to provide a complete account of the literature, including the Tacke article, published in 2005 by its own employees. (EX1003, ¶154.) Given Tacke's express disclosure that eculizumab contains IgG2/G4 isotype, a POSA would have found it unambiguous that eculizumab has Mueller PCT's IgG2/G4 constant region, not Thomas' IgG4 constant region. (*See supra* VIII.D.) But, as a result of Alexion's inaccurate statements regarding the literature as of the priority date, the Examiner overlooked these critical disclosures of Tacke and Mueller PCT. (*See also* EX1003, ¶154.)

**(b) Error 2: The Examiner Erred in Evaluating Bowdish and Evans**

*Second*, the Examiner erred in evaluating Bowdish and Evans by relying on Alexion's misleading comparison of Bowdish's IgG2/G4 TPO-mimetic compound, which is a humanized antibody, with Evans' mouse 5G1.1 sequence. *See Liquidia Techs., Inc. v. United Therapeutics Corp.*, IPR2020-00770, Paper 7 at 14-15 (PTAB Oct. 13, 2020) (although the examiner rejected the claims based on the same art that was cited in IPR filings listed in an IDS, the Board declined to deny institution

---

<sup>7</sup> Alexion listed Kaplan 2002 among these references, but its characterization of that article is incorrect. Kaplan expressly refers to Evans for the composition of eculizumab.


because the “examiner erred in relying on the applicant’s argument ... to allow the challenged claims.”). During prosecution, Alexion provided an alignment of Evans’ 5G1.1 *mouse* antibody variable regions with Bowdish’s sequence rather than using Evans’ 5G1.1 *humanized* variable region. This, unsurprisingly, revealed a mismatch in the sequences. (EX1036, 014.) The Examiner was persuaded by Alexion’s comparison, as evidenced by the Reason for Allowance:

Evan’s [*sic*] scaffold 5G1.1 mouse antibody variable regions or the whole 5G1.1 mouse antibody with the sequences for Bowdish’s TPO mimetic compound would still have revealed a mismatch in amino acids beyond those that Bowdish identified as the TPO mimetic peptide insert.

(EX1035, 006-07; EX1003, ¶155.) In fact, a comparison of Evans’ *humanized* sequence with Bowdish’s sequence—which is the correct, apples to apples, comparison for the humanized 5G1.1 antibody that a POSA would make—would have shown the Examiner that there is no mismatch beyond the HCDR3 region of the TPO mimetic peptide insert, as shown below:

Petition for *Inter Partes* Review of  
U.S. Patent No. 9,732,149 B2

Bowdish SEQ ID NO: 69	1	DIQMTQSPSSLSASVGDRVTITCG	ASENIYGALN	WYQ	KPGKAPKLLIYG	ATNLADGVPSR	FGSGSGTDFTLT	ISSLQP	80
Evans h5G1.1	1	DIQMTQSPSSLSASVGDRVTITCG	ASENIYGALN	WYQ	KPGKAPKLLIYG	ATNLADGVPSR	FGSGSGTDFTLT	ISSLQP	80
			CDR1			CDR2			
Bowdish SEQ ID NO: 69	81	EDFATYYCQ	NVLNTP	PLTF	GG	GTKVEIKRT			109
Evans h5G1.1	81	EDFATYYCQ	NVLNTP	PLTF	GG	GGSGGGGGSGGGG			124
			CDR3						
Bowdish SEQ ID NO: 67	1	QVQLVQSGAEVKKPGASVKV	SKASGYIFS	NYWIQ	WVRQAPGQGLEWMGE	ILPGSGSTEY	TENFKDRVT	MT	80
Evans h5G1.1	125	QVQLVQSGAEVKKPGASVKV	SKASGYIFS	NYWIQ	WVRQAPGQGLEWMGE	ILPGSGSTEY	TENFKDRVT	MT	204
				CDR1		CDR2			
Bowdish SEQ ID NO: 67	81	MELSSLRSEDTAVYYC	AR	P	IEGPTLRQWL	AARAPV	WG	Q	127
Evans h5G1.1	205	MELSSLRSEDTAVYYC	ARY	F	FGSSP	NWY	FDV	WG	246
				CDR3					



(EX1003, ¶156.) Indeed, a proper comparison would have shown the Examiner that the starting variable region sequence used by Bowdish is identical to the Evans sequence, and that Bowdish swapped out the HCDR3 region of Evans for the TPO mimetic peptide. Thus, a POSA could reconstruct *humanized* 5G1.1 by reversing this step. (See EX1003, ¶156.) Tellingly, Alexion did not share any such alignments with the Examiner during prosecution, even though they plainly could have.

Alexion also misled the Examiner that Bowdish’s “[c]onstruction of 5G1.1” would have directed a POSA only to Evans’ mouse antibody in Examples 7-10 (EX1036, 013.) Alexion’s argument conveniently ignores the express description of other examples in Evans. Specifically, Evans’ Example 11 expressly teaches

humanized 5G1.1 scFv **constructs** and is entitled “**Construction** and Expression of Recombinant mAbs.” (EX1005, 42:56-45:33 (emphasis added).) Example 11 also states: “Recombinant DNA **constructions** encoding the recombinant mAbs comprising the 5G1.1 CDRs are prepared by conventional recombinant DNA methods[.]” (EX1005, 42:59-62 (emphasis added).) Evans also discloses “CDR sequences that are useful in the **construction** of the humanized antibodies of the invention[.]” (EX1005, 8:50-54 (emphasis added).) By comparison, Alexion focused the Examiner on Example 7, entitled “Preparation of anti-C5 Monoclonal Antibodies,” which discloses preparing (not constructing) the parent 5G1.1 mouse antibody from the mouse hybridomas of the prior art. (EX1005, 37:34-39:30.) This misdirection by Alexion is relevant because a POSA considering Bowdish’s “construction of 5G1.1” for assembly of a full-length antibody by recombinant means would have referred to Evans’ construction of the humanized 5G1.1 scFv constructs detailed in Example 11, not Example 7. (*See also supra* VIII.C-D; EX1003, ¶157.)

Further, the Examiner misapprehended Evans by relying on Alexion’s mischaracterization that Evans discloses “multiple options” for heavy chain CDR3 sequence. In its Response, Alexion argued that even if a POSA were to consider Evans “for its disclosure of heavy chain CDR3 sequences, Evans et al. allows for multiple options, and nothing in Bowdish et al. or Evans et al. indicates which, if

any, were used in the ‘scaffold’ antibody used to produce Bowdish et al.’s TPO-mimetic peptide[.]” (EX1036, 018 (citation omitted).) This is a blatant misrepresentation of Evans — all nine humanized scFv sequences of Evans have only one unique HCDR3 sequence (YFFGSSPNWYFDV), not “multiple options.” (See EX1005, 42:56-45:33; *see also supra* VIII.C; EX1003, ¶158, Appendix A.) Alexion’s misinformation regarding Evans’ unique HCDR3 sequence for h5G1.1 misled the Examiner into allowing the claims during prosecution.

**(c) Error 3: The Examiner Misapplied the Law in  
Evaluation of Secondary Considerations**

*Third*, the Examiner materially erred by misapplying the law in evaluating the evidence of secondary considerations submitted by Alexion during prosecution. *Advanced Bionics*, Paper 6 at 8-9 n.9 (“An example of a material error ... may include an error of law[.]”). In the statement of Reasons for Allowance, the Examiner noted that “some of the secondary considerations are evidence of nonobviousness, particularly the invention as claimed satisfies a long felt need and that there is objective evidence of copying.” (EX1035, 007.) However, Alexion’s arguments for these secondary considerations are insufficient evidence of non-obviousness as a matter of law. (EX1003, ¶159.)

The Examiner erred in accepting Alexion’s evidence for long-felt need. Alexion derived its evidence of long-felt need from the success of its drug Soliris (eculizumab). (EX1036, 024-26.) But as described above, eculizumab as a PNH

therapy was indisputably in the prior art. (*See supra* IX; EX1003, ¶¶144, 159.)

For copying, the Examiner also misapplied the law in accepting Alexion's evidence. Alexion submitted four separate biosimilars as its evidence of copying. (EX1036, 026-27.) However, with biosimilars, as with Hatch-Waxman/ANDA cases, evidence of copying is not probative of nonobviousness because a showing of bioequivalence is required for FDA approval. *See, e.g., Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc.*, 25 F.4th 1354, 1374 (Fed. Cir. 2022) (holding that copying in ANDA context is not probative of nonobviousness). "Copying" by biosimilar applicants is entitled to no weight as a secondary consideration of nonobviousness. (*See supra* IX.) The Examiner therefore erred in considering development of biosimilars as evidence of copying. (EX1003, ¶¶146, 159.)

## **XI. CONCLUSION**

Petitioner respectfully requests institution of IPR based on the grounds set forth and described above.

Dated: May 18, 2023

Respectfully submitted,

COOLEY LLP  
ATTN: Patent Group  
1299 Pennsylvania Avenue NW  
Suite 700  
Washington, DC 20004  
Tel: (650) 843-5505  
Fax: (650) 849-7400

By: / Michelle S. Rhyu /  
Michelle S. Rhyu  
Reg. No. 41,268  
Counsel for Petitioner

## **CERTIFICATE OF COMPLIANCE WITH WORD COUNT**

Pursuant to 37 C.F.R. § 42.24(d), I certify that this petition complies with the type-volume limits of 37 C.F.R. § 42.24(a)(1)(i) because it contains 11,283 words, according to the word-processing system used to prepare this petition, excluding the parts of this petition that are exempted by 37 C.F.R. § 42.24(a) (including the table of contents, a table of authorities, mandatory notices, a certificate of service or this certificate word count, appendix of exhibits, and claim listings).

DATED: May 18, 2023

COOLEY LLP  
ATTN: Patent Group  
1299 Pennsylvania Avenue NW  
Suite 700  
Washington, D.C. 20004  
Tel: (650) 843-5505  
Fax: (650) 849-7400

/ Michelle S. Rhyu /  
Michelle S. Rhyu  
Reg. No. 41,268



## **CERTIFICATE OF SERVICE**

I hereby certify, pursuant to 37 C.F.R. Sections 42.6 and 42.105, that a complete copy of the attached **PETITION FOR INTER PARTES REVIEW OF U.S. PATENT NO. 9,732,149 B2**, including all exhibits (**Nos. 1001-1054**) and related documents, are being served via Federal Express on the May 18, 2023, the same day as the filing of the above-identified document in the United States Patent and Trademark Office/Patent Trial and Appeal Board, upon Patent Owner by serving the correspondence address of record with the USPTO as follows:

NELSON MULLINS RILEY & SCARBOROUGH LLP,  
One Financial Center, Ste. 3500  
Boston, MA 02111

DATED: May 18, 2023

/ Michelle S. Rhyu /  
Michelle S. Rhyu  
Reg. No. 41,268  
COOLEY LLP  
1299 Pennsylvania Ave. NW,  
Suite 700  
Washington, D.C. 20004  
Tel: (650) 843-5505